[
  {
    "date": "2023-12-31",
    "symbol": "CYTO",
    "period": "FY",
    "otheroperatingincomeexpense": 255589,
    "researchanddevelopmentexpense": 3035413,
    "generalandadministrativeexpense": 3136275,
    "profitlossfromoperatingactivities": -5916099,
    "otherfinanceincome": 354093,
    "otherfinancecost": 1668475,
    "shareofprofitlossofassociatesandjointventuresaccountedforusingequitymethod": -39557,
    "profitlossbeforetax": -7270038,
    "profitlossfromcontinuingoperations": -7270038,
    "profitlossfromdiscontinuedoperations": 3400865,
    "profitlossattributabletoownersofparent": -3869173,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 31163,
    "othercomprehensiveincomenetoftaxhedgesofnetinvestmentsinforeignoperations": 208848,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": 6869,
    "othercomprehensiveincomenetoftaxchangeinvalueoftimevalueofoptions": 246880,
    "comprehensiveincomeattributabletoownersofparent": -3622293,
    "basicearningslosspershare": -7.88,
    "basicearningslosspersharefromcontinuingoperations": -14.8,
    "dilutedearningslosspershare": -7.88,
    "dilutedearningslosspersharefromcontinuingoperations": -14.8,
    "propertyplantandequipment": 1,
    "rightofuseassets": 80110,
    "intangibleassetsotherthangoodwill": 3893681,
    "othernoncurrentreceivables": 80001,
    "investmentsinsubsidiariesjointventuresandassociates": 2417312,
    "noncurrentassets": 6471105,
    "othercurrentreceivables": 74823,
    "currentprepayments": 283832,
    "currentderivativefinancialassets": 247090,
    "cashandcashequivalents": 617409,
    "currentassets": 1223154,
    "assets": 7694259,
    "issuedcapital": 2646,
    "sharepremium": 20102873,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": 4399200,
    "retainedearnings": -18046002,
    "equityattributabletoownersofparent": 6458717,
    "noncurrentprovisionsforemployeebenefits": 346628,
    "noncurrentliabilities": 346628,
    "othercurrentfinancialliabilities": 99659,
    "tradeandothercurrentpayables": 440414,
    "accrualsclassifiedascurrent": 348841,
    "currentliabilities": 888914,
    "liabilities": 1235542,
    "equityandliabilities": 7694259,
    "equity": 2646,
    "othercomprehensiveincome": 215717,
    "othercomprehensiveincomebeforetax": 215717,
    "increasedecreasethroughexerciseofwarrantsequity": 486587,
    "proceedsfromissuingshares": 1052546,
    "proceedsfromexerciseofwarrants": 143,
    "increasedecreasethroughtransactionswithowners": 809378,
    "increasedecreasethroughconversionofconvertibleinstruments": 1131043,
    "reclassificationequitycomponentonconversionorrepayment": 469151,
    "recognitionofequitycomponentofloanswithwarrants": 475842,
    "valueofwarrantsandprefundedwarrants": -4086688,
    "gainsonchangeinfairvalueofderivatives": 8376,
    "reductionofissuedcapital": -2903684,
    "reductionofsharepremium": -186852242,
    "impairmentlossrecognisedinprofitorloss": -161249,
    "increasedecreasethroughsharebasedpaymenttransactions": 379414,
    "profitloss": 3869173,
    "adjustmentsfordepreciationexpense": 119304,
    "adjustmentforgainondisposalofdiscontinuedoperations": 5205535,
    "adjustmentsforunrealisedforeignexchangelossesgains": 180349,
    "adjustmentsforinterestexpense": 1007690,
    "adjustmentsforsharebasedpayments": 379414,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 41585,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -166192,
    "adjustmentsforfairvaluegainslosses": -29461,
    "adjustmentsforincometaxexpense": -99847,
    "adjustmentsforreconcileprofitloss": -7269925,
    "adjustmentsfordecreaseincreaseininventories": -319821,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 14062,
    "adjustmentsforincreasedecreaseinprepayments": 197011,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -3299680,
    "adjustmentsforincreasedecreaseinaccruedexpenses": -832711,
    "cashflowsfromusedinoperations": -11511064,
    "investmentinothernoncurrentreceivables": -10040,
    "purchaseofinterestsininvestmentsaccountedforusingequitymethod": 490000,
    "interestreceivedclassifiedasinvestingactivities": 505,
    "disposalofsubsidiaries": 1924324,
    "cashflowsfromusedininvestingactivities": 1444869,
    "proceedsfromissuingsharesfollowonoffering": 10507223,
    "paymentsforshareissuecosts": 786292,
    "proceedsfromloan": 2500000,
    "repaymentofloan": 1335562,
    "repaymentofleaseliabilities": 115413,
    "interestpaidclassifiedasfinancingactivities": 148341,
    "cashflowsfromusedinfinancingactivities": 10621615,
    "increasedecreaseincashandcashequivalents": 555420,
    "effectofexchangeratechangesoncashandcashequivalents": 46594,
    "consolidationpolicy1policytextblock": "Basis of consolidation",
    "assetpurchasepolicytextblock": "Asset purchase",
    "disclosureofdetailedinformationaboutforeigncurrencyratesexplanatorytabletextblock": "Closing rates for the most significant foreign currenciesrelative to CHF:",
    "disclosureoflowvalueandshorttermleaseexpensesexplanatory": "December 31,      December 31,       Low    value and short-term lease expenses     2023      2022       Expense    related to short-term leases      6,600       6,001       Expense    related to leases of low value assets              -       Total      6,600       6,001",
    "disclosureofleaseliabilitiesexplanatory": "December 31,      December 31,       Lease liabilities     2023      2022       As of January 1      461,485       575,736       Additions      -       -       Interest expense      19,294       15,949       Repayment of lease liability      (134,707)      (130,200)      Remeasurement (revised lease term)      (246,413)      -       As of December 31      99,659       461,485                              thereof non-current      -       343,629       thereof current      99,659       117,856",
    "scheduleofmaturitiesofleaseliabilitiestabletextblock": "December 31,      December 31,       Maturities    of lease liabilities     2023      2022       Year    1      101,030       130,200       Year    2      -       130,200       Year    3      -       130,200       Year    4      -       97,650       Year    5                      Undiscounted    lease payments      101,030       488,250       Less:    unearned interest      (1,371)      (26,765)      Total      99,659       461,485",
    "disclosureofotherreceivablestabletextblock": "December 31,      December 31,             2023      2022       R&D tax credit receivable      -       672,600       Value added tax receivable      22,036       78,650       Receivable from suppliers and other      52,787       4,737       Total other receivables      74,823       755,987",
    "disclosureofcashandcashequivalentexplanatory": "December 31,      December 31,             2023      2022       Cash    in bank accounts      617,409       15,395       Cash    on hand      -       -       Total    cash and cash equivalents      617,409       15,395",
    "disclosureofcommonsharestabletextblock": "Common    Shares             (Number)             2023      2022       As of January    1      59,003       37,411       Exercise of warrants      81,274       -       Public Offering      555,556       -       LPC equity line      17,500       15,750       ATM program      104,147       5,842       Conversion convertible loans      660,345       -       Fractional    shares eliminated upon reverse split      (40)      -       Total,    as of December 31      1,477,785       59,003",
    "scheduleoftradeandotherpayablestabletextblock": "December 31,      December 31,             2023      2022       Trade accounts    payable - third parties      413,111       4,767,940       Other      27,303       146,464       Total    trade and other payables      440,414       4,914,404",
    "disclosureofcomponentsofaccruedexpenses": "December 31,      December 31,             2023      2022       Accrued research    and development costs including milestone payments      87,522       741,291       Professional fees      17,412       326,365       Accrued vacation & overtime      52,368       46,868       Employee benefits incl. share    based payments      190,610       362,497       Accrued interest      -       457,812       Other      929       42,781       Total    accrued expenses      348,841       1,977,614",
    "disclosureofdeferredincometabletextblock": "December 31,      December 31,             2023      2022       Upfront payment          -       932,200       Total    deferred income      -       932,200",
    "disclosureofotheroperatingincomesexplanatory": "2023      2022      2021       Income from Government grants      228,302           -             -       Other    income      27,287       9,327       -       Total    other operating income      255,589       9,327       -",
    "disclosureofeffectiveincometaxexpensetabletextblock": "TheCompany’s effective income tax expense differed from the expected theoretical amount computed by applying the Company’s applicableweighted average tax rate of 15.8% in 2023 (2022: 13.7%, 2021: 13.5%) as summarized in the following table:",
    "disclosureofunrecognizedtaxlosscarryforwardstabletextblock": "TheCompany’s unrecognized tax loss carryforwards with their expiry dates are as follows:",
    "disclosureoftaxeffectunrecognizedlosscarryforwardstabletextblock": "Thetax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below:",
    "disclosureofdetailedinformationaboutearningspershareexplanatory": "Loss    per share     2023      2022      2021       Loss attributable    to owners of the Company      (3,869,173)      (26,528,411)      (17,058,443)      Weighted average number of shares outstanding      491,258       45,536       33,116       Basic and diluted loss per share      (7.88)      (582.58)      (515.11)",
    "disclosureofgainondisposalofdiscontinuedoperationstabletextblock": "Thegain on disposal of discontinued operations was determined as follows:",
    "disclosureofdetailedinformationaboutrelatedpartytransactions": "In 2023, the compensationpaid to management, excluding share bonuses and share-based payment charge, amounted to CHF 681,353 (2022: CHF 1,038,810; 2021: CHF 810,671).The fees paid to members of the Board of Directors in 2023 for their activities as board members totaled CHF 138,507 (2022: CHF 183,058;2021: CHF 165,245).",
    "scheduleofconvertibleloanagreementtextblock": "Convertibleloan agreements",
    "reportingentities": 5,
    "closingforeignexchangerate": 1,
    "averageforeignexchangerate": 1,
    "usefullivesordepreciationratespropertyplantandequipmentperiod": "P5Y",
    "financialassets": 617409,
    "financialliabilities": 440413,
    "tradeandotherpayables": 440413,
    "currentaccruedexpensesandothercurrentliabilities": 348841,
    "currentleaseliabilities": 99659,
    "currentfinancialliabilitiesatamortisedcost": 888913,
    "financialassetsliabilities": "Asset247,090",
    "issuessettlementsfairvaluemeasurementliabilities": 1164438,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": 166192,
    "otherincreasedecreaseinfairvaluemeasurementliabilities": -7200427,
    "derivativefinancialinstruments": 99659,
    "maximumexposuretocreditrisk": 617409,
    "riskexposureassociatedwithinstrumentssharingcharacteristic": 7637,
    "noncurrentassetsotherthanfinancialinstrumentsdeferredtaxassetspostemploymentbenefitassetsandrightsarisingunderinsurancecontracts": 3973792,
    "propertyservicechargeexpense": 119304,
    "cost": 348023,
    "accumulateddepreciation": -267913,
    "netbookvalue1": 80110,
    "remeasurementrevisedleasetermindollars": -246413,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 6600,
    "lowvalueandshorttermleaseexpensestotal": 6600,
    "leaseliabilities": 99659,
    "interestexpenseonleaseliabilities": 19294,
    "repaymentofleaseliability": -134707,
    "thereofcurrent": 99659,
    "maturitiesofleaseliabilitiesyear1": 101030,
    "undiscountedleasepayments": 101030,
    "lessunearnedinterest": -1371,
    "maturitiesofleaseliabilitiestotal": 99659,
    "intangibleassetsotherthangoodwilladditionsnetbookvalue1": 5376201,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 168,
    "accumulatedamortizationandimpairmentlossendingbalance": -1482520,
    "shareinequity": -45759,
    "goodwill": 2463071,
    "sharesinequity": 0.49,
    "revenuefromcontractswithcustomers": 379,
    "costofsales": 33967,
    "operatingexpense": 29321,
    "financecost": 15732,
    "profitbeforetax": 78641,
    "incometaxexpenses": 2087,
    "profitaftertax": 80728,
    "othercomprehensiveincomes": 14018,
    "othercomprehensiveincomethatwillnotbereclassifiedtoprofitorlossbeforetax": -66710,
    "currentvalueaddedtaxreceivables": 22036,
    "currentreceivablesfromothersources": 52787,
    "otherreceivables": 74823,
    "currentprepaymentsandothercurrentassets": 212579,
    "currentprepaidinsurance": 71253,
    "balanceswithbanks": 617409,
    "cash": 6500000,
    "numberofsharesissued": 1477785,
    "parvaluepershare": 0.002,
    "numberofsharesoutstanding": 1477785,
    "exerciseofwarrants": 81274,
    "publicoffering": 555556,
    "lpcequityline": 17500,
    "atmprogram": 104147,
    "conversionconvertibleloan": 660345,
    "fractionalshareseliminateduponreversesplit": -40,
    "numberofoutstandingshareoptions": 7898,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "1 year service from grant date",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm2": "P6Y",
    "descriptionofinputsusedinfairvaluemeasuremententitysownequityinstruments": "USD 1.72 (2 year vesting) 1) USD 1.96 (3 year vesting) 1)",
    "sharepriceforfairvaluemeasurementonequity": "USD 2.92",
    "exercisepriceforfairvaluemeasurementonequity": "USD 2.92",
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.0734,
    "descriptionofoptionslifeshareoptionsgranted": "2 and 3 years",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0425,
    "weightedaverageexercisepriceoutstanding": 22.17,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions": "P6Y2M19D",
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangements": -1467,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangements": 138907,
    "weightedaverageexercisepricegranted": 4.76,
    "numberofoutstandingsharesoptionoutstanding": 145324,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions1": "P5Y7M13D",
    "numberofshareoptionsexercisableinsharebasedpaymentarrangements": 2630,
    "tradeandotherpayablestotradesuppliers": 413111,
    "othercurrentpayables": 27303,
    "totaltradeandotherpayables": 440414,
    "currentresearchanddevelopmentprovision": 87522,
    "currentprofessionalfeesaccruals": 17412,
    "currentvacationandovertimeaccruals": 52368,
    "shorttermemployeebenefitsaccruals": 190610,
    "othercurrentliabilities": 929,
    "accrualclassifiedascurrent": 348841,
    "incomefromrdtaxincentive": 228302,
    "otherincome": 27287,
    "revenueandoperatingincome": 255589,
    "preclinicalprojects": 505031,
    "clinicalprojects": 128717,
    "drugmanufacturingandsubstance": 364392,
    "leaseandsubleasepaymentsrecognisedasexpense": 1429564,
    "patentsandtrademarks": 414718,
    "regulatoryprojects": 59531,
    "otherresearchanddevelopmentexpenses": 133459,
    "generalemployeebenefitsexpense": 655967,
    "businessdevelopmentexpenses": 15348,
    "travelexpense": 43055,
    "administrativeexpense": 2274159,
    "generalleaseandsubleasepaymentsrecognisedasexpense": 15705,
    "depreciationrightofuseassetsindollars": 119304,
    "capitaltaxexpenses": 12738,
    "sellinggeneralandadministrativeexpense": 3136275,
    "wagesandsalaries": 2145943,
    "pensioncosts": 172460,
    "othershorttermemployeebenefits": 293753,
    "expensefromsharebasedpaymentstransactionwithemployees": 379414,
    "otherpersonnelexpenditures": 9999,
    "employeebenefitsexpense": 3001569,
    "employeebenefitsattributabletocontinuingoperations": 2243955,
    "employeebenefitsattributabletodiscontinuedoperations": 757614,
    "recognisedliabilitiesdefinedbenefitplan": 3940179,
    "pastservicecostnetdefinedbenefitliabilityasset": 163101,
    "currentservicecostnetdefinedbenefitliabilityassetplanparticipantscontribution": 130875,
    "interestcost": 76139,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": 104860,
    "increasedecreasebenefitspaidthroughpensionassetsindollars": -78957,
    "liabilityassetofdefinedbenefitplan": 3593551,
    "adjustmentsforinterestincome": 71813,
    "returnonplanassetsexcludinginterestincome": 136023,
    "contributionstoplanbyemployernetdefinedbenefitliabilityasset": 130875,
    "contributionstoplanbyplanparticipantsnetdefinedbenefitliabilityasset": 130875,
    "employeeobligationtobenefitspaidthroughpensionassetsindollars": -78957,
    "administrativeexpensesnetdefinedbenefitliabilityasset": -5033,
    "planassetsatfairvalue": 3593551,
    "definedbenefitobligationatpresentvalue": 3940179,
    "currentservicecostnetdefinedbenefitliabilityasset": 163101,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 3270,
    "administrativeexpensenetdefinedbenefitliabilityasset": 4259,
    "postemploymentbenefitexpensedefinedbenefitplans": 170630,
    "actuarialgainslossesarisingfromchangesinfinancialassumptionsnetdefinedbenefitliabilityasset": 247262,
    "actuarialgainslossesarisingfromexperienceadjustmentsnetdefinedbenefitliabilityasset": -138497,
    "actuarialgainslossesarisingfromchangesindemographicassumptionsnetdefinedbenefitliabilityasset": -3905,
    "returnonplanassetsnetdefinedbenefitliabilityasset": 136023,
    "othercomprehensiveincomebeforetaxgainslossesonremeasurementsofdefinedbenefitplans": -31163,
    "actuarialassumptionofdiscountrates": 0.015,
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.0135,
    "descriptionofassetliabilitymatchingstrategiesusedbyplanorentitytomanagerisk": "BVG2020",
    "percentageofreasonablypossibleincreaseinactuarialassumptions": "0.25% increase",
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": -141340,
    "lifeexpectancyreasonablypossibleincreaseinactuarialassumption": "+1 year",
    "gainonmodificationoffinancialinstruments": 36778,
    "revaluationlossfromderivativefinancialinstrumentsindollars": 181258,
    "lossonmodificationoffinancialinstruments": 7317,
    "financeincomecost": -131192,
    "deferredincometaxgainfromdiscontinuedoperations": 99847,
    "incometaxgain": 99847,
    "profitbeforeincometaxfromdiscontinuedoperations": 3301018,
    "accountingprofit": -3969020,
    "taxeffectofforeigntaxrates": 626286,
    "incometaxreconciliationunrecognizedtemporarydifferences": -5423,
    "incometaxreconciliationunrecognizedtaxablelossesinequity": -543086,
    "incometaxreconciliationdeductionimpactfromapplicationofdifferenttaxrates": -43534,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 65604,
    "incometaxexpensecontinuingoperation": 99847,
    "incometaxgainlossattributabletodiscontinuedoperations": 99847,
    "deferredtaxassetoperatinglosscarryforward": 60600000,
    "employeebenefitplan": 45200,
    "offsettingpotentialtaxliabilities": 45200,
    "potentialtaxassetsfromlosscarryforwardsnotrecognized": 7936946,
    "potentialtaxassetsfromlosscarryforwardsandtemporarydifferencesnotrecognized": 7982146,
    "weightedaverageshares": 491258,
    "profitlossfromcontinuingoperationsattributabletoordinaryequityholdersofparententity": -7270038,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 491258,
    "basicearningslossperinstrumentfromcontinuingoperationsparticipatingequityinstrumentsotherthanordinaryshares": -14.8,
    "dilutedearningslossperinstrumentfromcontinuingoperationsparticipatingequityinstrumentsotherthanordinaryshares": -14.8,
    "revenue": 157834,
    "currenttaxexpenseincome": -99847,
    "gainlossrecognisedonmeasurementtofairvaluelesscoststosellorondisposalofassetsordisposalgroupsconstitutingdiscontinuedoperation": 5205535,
    "basicearningslosspersharefromdiscontinuedoperations": 6.92,
    "dilutedearningslosspersharefromdiscontinuedoperations": 6.92,
    "cashflowsfromusedinoperatingactivitiesdiscontinuedoperations": -1092385,
    "cashflowsfromusedininvestingactivitiesdiscontinuedoperations": 67,
    "cashflowsfromusedinfinancingactivitiesdiscontinuedoperations": 1056532,
    "increasedecreaseincashandcashequivalentsdiscontinuedoperations": -35786,
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 3946,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 636884,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 44469,
    "keymanagementpersonnelcompensationsharebasedpayment": 681353,
    "keymanagementpersonnelcompensation": 923622,
    "balanceatbeginning": 4898377,
    "grossproceedsatdisbursementdate": 2500000,
    "embeddedderivativeseparated": -435023,
    "carryingamountatinitialrecognition": 6963354,
    "repaymentincash": -285562,
    "convertedprincipalamount": -7214438,
    "amortizationtransactioncostsandderivative": 536646,
    "proportionofownershipinterestinsubsidiary": 1,
    "investmentfundspercentagecontributedtofairvalueofplanassets": 0.49,
    "spinningoffpercentage": 0.51,
    "taxterm": "P7Y",
    "taxrateeffectoftaxlosses": 0.8,
    "usefullivesoramortisationratesintangibleassetsotherthangoodwillperiod": "P10Y",
    "nonregisteredcommonshares": 1911,
    "dividendspaidordinarysharespershare": 4,
    "averageclosingprice": 2500000,
    "tradingdays": "P15D",
    "referencepriceamount": 1308,
    "sellingexpense": 210000,
    "royaltyterm": "P12Y",
    "aggregatecost": 4375000,
    "transactioncosts": 198246,
    "leasesamount": 5000,
    "grantedshareoptionpercentage": 0.5,
    "grantedterm": "P2Y",
    "remaininggrantedpercentage": 0.5,
    "taxoffsetpercentage": 0.435,
    "researchanddevelopmentexpenditurespercentage": 0.485,
    "taxrateeffectofforeigntaxrates": 0.05,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariableimpactonpretaxearnings": 57870,
    "amountspayablerelatedpartytransactions": 1000000,
    "cashtransferred": 490000,
    "receivablesfromsaleofproperties": 18905,
    "commonsharesparvalue": 0.0001,
    "commonshares": 81274,
    "grossproceeds": 5000000,
    "transactionpriceallocatedtoremainingperformanceobligations": 718767,
    "classofwarrantsorrightsissued": 3921647,
    "averageeffectivetaxrate": 0.158,
    "aggregatecashpayments": 387045,
    "averageprice": 443294,
    "averagepricepershares": 5.07,
    "exerciseprice": 30.76,
    "numberofsharesauthorised": 5000000,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangementshares": 138907,
    "expensefromsharebasedpaymenttransactionswithemployees": 379414,
    "exercisepriceofoutstandingsharesoption": 2.46,
    "interestrateterm": "P2Y",
    "actuarialassumptionsminimumretirementsavinginterestrate": 0.01,
    "weightedaveragedurationofdefinedbenefitobligation1": "P17Y8M12D",
    "estimateofcontributionsexpectedtobepaidtoplan": 128608,
    "revaluationofoutstandingwarrants": 15066,
    "othercomprehensiveincomenetoftaxgainslossesonrevaluation": 181258,
    "interestexpense": 1007437,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 145324,
    "adjustedweightedaverageshares": 45536,
    "warrantstopurchase": 759167,
    "percentageofretainedshares": 0.49,
    "minimumoperatingleasepayments": 6600,
    "interestreceivable": 18905,
    "auditorsremuneration": 251110,
    "adjustmentsforsharebasedpayment": 283588,
    "relatedpartytransactions": 99318,
    "descriptionofexpectedvolatilityrate": 0.907,
    "fairvaluemeasurementamount": 449898,
    "transactionscosts": 807593,
    "prefundedwarrants": 112597,
    "entityregistrantname": "ALTAMIRA THERAPEUTICS LTD.",
    "tradingsymbol": "CYTO",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1601936,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36582",
    "entityincorporationstatecountrycode": "D0",
    "entityaddressaddressline1": "Clarendon House",
    "entityaddressaddressline2": "2 Church Street",
    "entityaddresscityortown": "Hamilton",
    "entityaddresspostalzipcode": "HM11",
    "entityaddresscountry": "BM",
    "contactpersonnelname": "Thomas Meyer",
    "cityareacode": "+1 (441)",
    "localphonenumber": "295 59 50",
    "security12btitle": "Common Shares, par value USD 0.002 per share",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1235,
    "auditorname": "Roland Mueller",
    "auditorlocation": "Zurich, Switzerland"
  },
  {
    "date": "2022-12-31",
    "symbol": "CYTO",
    "period": "FY",
    "revenue": 305616,
    "costofsales": 1443855,
    "grossprofit": -1138239,
    "otheroperatingincomeexpense": 709449,
    "researchanddevelopmentexpense": 19677756,
    "salesandmarketingexpense": 249688,
    "generalandadministrativeexpense": 3644549,
    "profitlossfromoperatingactivities": -26132479,
    "investmentincome": 969,
    "interestexpense": 911869,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 54645,
    "gainslossesonchangeinfairvalueofderivatives": 451131,
    "feeandcommissionexpense": 1137,
    "profitlossbeforetax": -26538740,
    "incometaxexpensecontinuingoperations": -10329,
    "profitlossattributabletoownersofparent": -26528411,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 441277,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 61046,
    "othercomprehensiveincome": 441277,
    "totalcomprehensivelossesattributabletoownersofthecompany": -26026088,
    "basicearningslosspershare": -29.13,
    "dilutedearningslosspershare": -29.13,
    "propertyplantandequipment": 1,
    "rightofuseassets": 445827,
    "intangibleassetsotherthangoodwill": 3893681,
    "othernoncurrentreceivables": 194263,
    "noncurrentassets": 4533772,
    "inventories": 11644,
    "tradeandothercurrentreceivables": 6525,
    "othercurrentreceivables": 755987,
    "currentprepayments": 709266,
    "currentderivativefinancialassets": 270176,
    "cashandcashequivalents": 15395,
    "currentassets": 1768993,
    "assets": 6302765,
    "issuedcapital": 236011,
    "sharepremium": 192622406,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": 258044,
    "retainedearnings": -201431272,
    "equityattributabletoownersofparent": -8314811,
    "noncurrentleaseliabilities": 343629,
    "noncurrentprovisionsforemployeebenefits": 336206,
    "deferredtaxliabilities": 932200,
    "deferredtaxliabilityasset": 125870,
    "noncurrentliabilities": 1737905,
    "currentportionoflongtermborrowings": 5869797,
    "othercurrentfinancialliabilities": 117856,
    "tradeandothercurrentpayables": 4914404,
    "accrualsclassifiedascurrent": 1977614,
    "currentliabilities": 12879671,
    "liabilities": 14617576,
    "equityandliabilities": 6302765,
    "equity": -8314811,
    "othercomprehensiveincomebeforetax": -26026088,
    "capitalincreaseexerciseofwarrants": 4232793,
    "transactioncost": -35495,
    "recognitionofequitycomponentofloanswithwarrantsindollars": 134929,
    "increasedecreasethroughsharebasedpaymenttransactions": 342799,
    "profitloss": 26528411,
    "adjustmentsfordepreciationexpense": 118887,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 12397148,
    "deferredincomes": 932200,
    "adjustmentsforunrealisedforeignexchangelossesgains": -46087,
    "adjustmentsforinterestexpense": 891651,
    "adjustmentsforsharebasedpayments": 342799,
    "transactionscosts": 807593,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 109164,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": 451131,
    "adjustmentsforincometaxexpense": -10329,
    "adjustmentsforreconcileprofitloss": -12242972,
    "adjustmentsfordecreaseincreaseininventories": 827577,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -103601,
    "adjustmentsforincreasedecreaseinprepayments": 856429,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1263196,
    "adjustmentsforincreasedecreaseinaccruedexpenses": 716140,
    "cashflowsfromusedinoperations": -8683231,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2142806,
    "interestreceivedclassifiedasinvestingactivities": 969,
    "cashflowsfromusedininvestingactivities": -2141837,
    "proceedsfromissuingsharesfollowonoffering": 3962618,
    "transactionscost": -35496,
    "proceedsfromloan": 6038627,
    "repaymentofleaseliabilities": 114251,
    "interestpaidclassifiedasfinancingactivities": 19503,
    "cashflowsfromusedinfinancingactivities": 9831995,
    "increasedecreaseincashandcashequivalents": -993073,
    "effectofexchangeratechangesoncashandcashequivalents": 24277,
    "disclosureofreportingentityexplanatorytextblock": "1. Reporting entity ",
    "rightofuseassetsandleaseliabilitiestextblock": "8.Right-of-use assets and lease liabilities ",
    "disclosureofsalesandmarketingexpensetextblock": "23. Sales and marketing expense ",
    "disclosureofloanstextblock": "31. Loans ",
    "disclosureofwarrantstextblock": "32. Warrants from Public Offering ",
    "consolidationpolicy1policytextblock": "Basis of consolidation ",
    "assetpurchasepolicytextblock": "Asset purchase ",
    "leasespolicytextblock": "Leases ",
    "inventoriespolicytextblock": "Inventories ",
    "disclosureofdetailedinformationaboutforeigncurrencyratesexplanatorytabletextblock": "                  Geographical     Reporting     December 31,      December 31,      December 31,       Currency           area     entities     2022      2021      2020       CHF     Swiss Franc     Switzerland     5      1.0000       1.0000       1.0000       USD     Dollar     United States     1      0.9251       0.9110       0.8840       EUR     Euro     Europe     1      0.9901       1.0361       1.0817       AUD     Dollar     Australia     1      0.6305       0.6620       0.6822    ",
    "estimatedusefullivestabletextblock": "      Production equipment     5 years      Office furniture and electronic data processing equipment (“EDP”)     3 years   ",
    "scheduleoflowvalueandshorttermleaseexpensestabletextblock": "            December 31,      December 31,       Low    value and short-term lease expenses     2022      2021                            Expense related to short-term leases      6,001       52,280       Expense related to leases of low value assets      —       —       Total      6,001       52,280    ",
    "scheduleofleaseliabilitiestabletextblock": "            December 31,      December 31,       Lease    liabilities     2022      2021       As of January 1      575,736       —       Additions      —       594,436       Interest expense      15,949       3,000       Repayment of lease liability      (130,200)      (21,700)      As of December 31      461,485       575,736                              thereof non-current      343,629       461,485       thereof current      117,856       114,251    ",
    "scheduleofmaturitiesofleaseliabilitiestabletextblock": "            December 31,      December 31,       Maturities    of lease liabilities     2022      2021                            Year 1      130,200       130,200       Year 2      130,200       130,200       Year 3      130,200       130,200       Year 4      97,650       130,200       Year 5      —       97,650       Undiscounted    lease payments      488,250       618,450       Less: unearned interest      (26,765)      (42,714)      Total      461,485       575,736   ",
    "disclosureofotherreceivablestabletextblock": "            December 31,      December 31,             2022      2021       R&D tax credit receivable      672,600       224,465       Receivable from share issuance      —       255,187       Value added tax receivable      78,650       168,851       Withholding tax receivable      —       7,336       Receivable from suppliers and other      4,737       15,501       Total other receivables      755,987       671,340    ",
    "disclosureofprepaymentstabletextblock": "            December 31,      December 31,             2022      2021       Advance payments to suppliers      659,861       1,437,708       Insurance      49,405       137,418       Total    prepayments      709,266       1,575,126   ",
    "disclosureofdetailedinformationforcashandcashequivalentstabletextblock": "            December 31,      December 31,             2022      2021       Cash in bank accounts      15,395       984,191       Cash on hand      —       —       Total cash and cash equivalents      15,395       984,191   ",
    "componentsofaccruedexpensesandotherliabilitiestabletextblock": "             December 31,      December 31,             2022      2021       Trade accounts payable - third parties      4,767,940       3,544,384       Other      146,464       153,339       Total trade and other payables      4,914,404       3,697,723   ",
    "scheduleofdeferredincometabletextblock": "             December 31,      December 31,             2022      2021       Upfront payment      932,200           —       Total deferred income      932,200       —    ",
    "scheduleofotheroperatingincometabletextblock": "            December 31,      December 31,      December 31,             2022      2021      2020       Income from R&D tax incentive (Government grants)      700,122       211,664       —       Refund of share issuance stamp duty      —       —       100,002       Other income      9,327       2,553       74,473       Total other operating income      709,449       214,217       174,475   ",
    "scheduleofcostofsalestabletextblock": "            December 31,      December 31,      December 31,             2022      2021      2020       Product purchases, packaging and logistics      362,584       173,758          —       Employee benefit and expenses      150,438       89,238       —       Inventory write-down      930,833       1,977,558       —       Total cost of sales      1,443,855       2,240,554       —   ",
    "disclosureofsalesandmarketingexpensetabletextblock": "            December 31,      December 31,      December 31,             2022      2021      2020       Marketing and sales expenses      2,131,696       1,132,864          —       Employee benefits and expenses      249,688       204,157       —       Product samples      —       161,167       —       Total sales and marketing      2,381,384       1,498,218       —   ",
    "disclosureofincometaxexpensetabletextblock": "            2022      2021      2020       Deferred income tax expense      (52,004)      (570,730)      (389,384)      Deferred income tax gain      62,332       549,110       410,668       Income tax gain/(loss)      10,329       (21,620)      21,284    ",
    "discloureofdeferredtaxesassetsandliabilitiestabletextblock": "            December 31,      December 31,       Deferred Tax Liabilities     2022      2021       Intangible assets      —       (51,914)      Deferred unrealized foreign exchange gains      —       —       Other receivables      (167,299)      (122,449)      Total      (167,299)      (174,363)   ",
    "disclosureofdetailedinformationabouttaxlosscarryforwards": "            December 31,      December 31,             2022      2021       Within 1 year      27,956,899       28,909,896       Between 1 and 3 years      31,668,498       50,673,943       Between 3 and 7 years      41,797,708       29,007,049       More than 7 years      1,691,572       1,264,262       Total      103,114,677       109,855,150    ",
    "disclosureofdetailedinformationaboutearningspershareexplanatory": "            December 31,      December 31,      December 31,             2022      2021      2020       Loss attributable to owners of the Company      (26,528,411)      (17,058,443)      (8,200,165)      Weighted average number of shares outstanding      910,723       662,314       300,707       Basic and diluted loss per share      (29.13)      (25.76)      (27.27)   ",
    "scheduleofloantextblock": "            December 31,      December 31,             2022      2021       Convertible loan February 2022      4,898,377       —       Loans with warrants      871,420       —       Short-term loan from related party      100,000       —       Total      5,869,797       —    ",
    "reportingentities": 1000,
    "closingforeignexchangerate": 630.5,
    "averageforeignexchangerate": 662.9000000000001,
    "usefullivesordepreciationratespropertyplantandequipmentperiod": 3,
    "financialassets": 486359,
    "financialliabilities": 13223300,
    "tradeandotherpayables": 4914404,
    "currentaccruedexpensesandothercurrentliabilities": 1977614,
    "borrowings": 6117069,
    "noncurrentleaseprepayments": 358050,
    "currentleaseliabilities": 130200,
    "derivativefinancialinstruments": 6331282,
    "currentfinancialassetsatamortisedcost": 13497337,
    "derivativefinancialassetsoptionlpcpurchaseagreement": "Asset 270,176",
    "increasedecreaseinvolatilityassumptionpercentage": -0.05,
    "issuessettlementsfairvaluemeasurementliabilities": 5908427,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": -1233,
    "otherincreasedecreaseinfairvaluemeasurementliabilities": -152881,
    "maximumexposuretocreditrisk": 216183,
    "riskexposureassociatedwithinstrumentssharingcharacteristic": 218261,
    "noncurrentasset": 4339509,
    "propertyservicechargeexpense": 118887,
    "cost": 594436,
    "accumulateddepreciation": -148609,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 6001,
    "lowvalueandshorttermleaseexpensestotal": 6001,
    "leaseliabilities": 461485,
    "thereofnoncurrent": 343629,
    "thereofcurrent": 117856,
    "interestexpenseonleaseliabilities": 15949,
    "repaymentofleaseliability": -130200,
    "maturitiesofleaseliabilitiesyear1": 130200,
    "maturitiesofleaseliabilitiesyear2": 130200,
    "maturitiesofleaseliabilitiesyear3": 130200,
    "maturitiesofleaseliabilitiesyear4": 97650,
    "undiscountedleasepayments": 488250,
    "lessunearnedinterest": -26765,
    "maturitiesofleaseliabilitiestotal": 461485,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 168,
    "intangibleassetsotherthangoodwilladditions": 1975784,
    "intangibleassetsotherthangoodwilladditionsnetbookvalue": 17820758,
    "accumulatedamortizationandimpairmentlossesbeginningbalance": -13927077,
    "impairmentindollars": -12397148,
    "netbookvalue": 3893681,
    "finishedgoods": 900000,
    "inventoriestotal": 11644,
    "valueaddedtaxreceivables": 672600,
    "currentvalueaddedtaxreceivables": 78650,
    "currentreceivablesfromothersources": 4737,
    "otherreceivables": 755987,
    "currentprepaymentsandothercurrentassets": 659861,
    "currentprepaidinsurance": 49405,
    "balanceswithbanks": 15395,
    "cash": 15395,
    "numberofsharesissued": 1180053,
    "parvaluepershare": 0.2,
    "numberofsharesoutstanding": 1180053,
    "lpcequityline": 315000,
    "atmprogram": 116843,
    "registereddirectoffering": -3,
    "numberofoutstandingshareoptions": 67682,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "3 years’ service from grant date (50%)",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm2": 8,
    "descriptionofinputsusedinfairvaluemeasuremententitysownequityinstruments": "USD 6.644 (1 year vesting) 2) USD 8.760 (2 year vesting) 2) USD 10.604 (3 year vesting) 2)",
    "sharepriceforfairvaluemeasurementonequity": "USD 17.8",
    "exercisepriceforfairvaluemeasurementonequity": "USD 20.78",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.991,
    "descriptionofoptionslifeshareoptionsgranted": "1, 2 and 3 years",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.028700000000000003,
    "numberofoutstandingshareoptionoutstanding": 157730,
    "weightedaverageexercisepriceoutstanding": 19.28,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions": 6.56,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangements": 28796,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangements": -6488,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangements": 97742,
    "weightedaverageexercisepricegranted": 9.4,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions1": 6.22,
    "tradeandotherpayablestotradesuppliers": 4767940,
    "othercurrentpayables": 146464,
    "currentresearchanddevelopmentprovision": 741291,
    "currentprofessionalfeesaccruals": 326365,
    "currentvacationandovertimeaccruals": 46868,
    "shorttermemployeebenefitsaccruals": 362497,
    "currentaccruedincomeincludingcurrentcontractassets": 457812,
    "othercurrentliabilities": 42781,
    "accrualclassifiedascurrent": 1977614,
    "upfrontpaymentofdeferredincome": 932200,
    "totaldeferredincome": 932200,
    "incomefromrdtaxincentive": 700122,
    "otherincome": 9327,
    "revenueandoperatingincome": 709449,
    "revenuefromsaleofgoodsrelatedpartytransactions": 305616,
    "revenueofcombinedentity": 305616,
    "purchasesofgoodsrelatedpartytransactions": 362584,
    "shorttermemployeebenefitsexpense": 150438,
    "inventorywritedown": 930833,
    "preclinicalprojects": 509224,
    "clinicalprojects": 3237649,
    "drugmanufacturingandsubstance": 473246,
    "employeebenefitsresearchanddevelopmentexpense": 2585242,
    "patentsandtrademarks": 240380,
    "regulatoryprojects": 153863,
    "impairmentintangibleassetsindollars": 12397148,
    "depreciationexpenseofresearchanddevelopmenttangibleassets": 81004,
    "generalemployeebenefitsexpense": 735139,
    "businessdevelopmentexpenses": 15727,
    "travelexpense": 95503,
    "administrativeexpense": 2669460,
    "generalleaseandsubleasepaymentsrecognisedasexpense": 6001,
    "depreciationrightofuseassetsindollars": 118887,
    "capitaltaxexpenses": 3832,
    "sellinggeneralandadministrativeexpense": 3644549,
    "wagesandsalaries": 2815411,
    "pensioncosts": 266256,
    "othershorttermemployeebenefits": 294017,
    "expensefromsharebasedpaymentstransactionwithemployees": 342799,
    "otherpersonnelexpenditures": 2024,
    "employeebenefitsexpense": 3720507,
    "recognisedliabilitiesdefinedbenefitplan": 3544161,
    "pastservicecostnetdefinedbenefitliabilityasset": 256336,
    "currentservicecostnetdefinedbenefitliabilityassetplanparticipantscontribution": 154116,
    "interestcost": 13762,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": -931636,
    "increasedecreasebenefitspaidthroughpensionassetsindollars": -626049,
    "liabilityassetofdefinedbenefitplan": 3207955,
    "adjustmentsforinterestincome": 12187,
    "returnonplanassetsexcludinginterestincome": -490359,
    "contributionstoplanbyemployernetdefinedbenefitliabilityasset": 154116,
    "contributionstoplanbyplanparticipantsnetdefinedbenefitliabilityasset": 154116,
    "employeeobligationtobenefitspaidthroughpensionassetsindollars": -626049,
    "administrativeexpensesnetdefinedbenefitliabilityasset": -5369,
    "planassetsatfairvalue": 3207955,
    "definedbenefitobligationatpresentvalue": 3544161,
    "currentservicecostnetdefinedbenefitliabilityasset": 256336,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 1575,
    "administrativeexpensenetdefinedbenefitliabilityasset": 5369,
    "postemploymentbenefitexpensedefinedbenefitplans": 263280,
    "actuarialgainslossesarisingfromchangesinfinancialassumptionsnetdefinedbenefitliabilityasset": -876841,
    "actuarialgainslossesarisingfromexperienceadjustmentsnetdefinedbenefitliabilityasset": -54795,
    "returnonplanassetsnetdefinedbenefitliabilityasset": -490359,
    "othercomprehensiveincomebeforetaxgainslossesonremeasurementsofdefinedbenefitplans": 441277,
    "actuarialassumptionofdiscountrates": 0.022000000000000002,
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.016,
    "descriptionofassetliabilitymatchingstrategiesusedbyplanorentitytomanagerisk": "BVG2020",
    "percentageofreasonablypossibleincreaseinactuarialassumptions": "0.25% increase",
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": 48531,
    "lifeexpectancyreasonablypossibleincreaseinactuarialassumption": "+1 year",
    "revenuefrominterest": 969,
    "netforeignexchangegain": 745260,
    "revaluationgainfromderivativefinancialinstruments": 451131,
    "financeincome": 1197360,
    "interestexpenseincludingbankcharges": 911869,
    "netforeignexchangeloss": 690615,
    "otherfinancecost": 1137,
    "financecosts": 1603621,
    "financeincomecost": -406261,
    "deferredincometaxexpenses": -52004,
    "deferredincometaxgain": 62332,
    "incometaxexpensecontinuingoperation": 10329,
    "taxexpenseincomeatapplicabletaxrate": 3641775,
    "incometaxreconciliationunrecognizedtemporarydifferences": -125260,
    "incometaxreconciliationunrecognizedtaxablelossesinequity": -3015088,
    "incometaxreconciliationdeductionimpactfromapplicationofdifferenttaxrates": -491098,
    "deferredtaxliabilitiy": 167299,
    "deferredtaxassets": 41429,
    "deferredtaxliabilitiesasset": -125870,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 10329,
    "exchangedifferences": 6285,
    "deferredtaxassetoperatinglosscarryforward": 103114677,
    "deferredincomeindollars": 111025,
    "employeebenefitplan": 43841,
    "offsettingpotentialtaxliabilities": 154866,
    "potentialtaxassetsfromlosscarryforwardsnotrecognized": 13297723,
    "potentialtaxassetsfromlosscarryforwardsandtemporarydifferencesnotrecognized": 13452589,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": -26528411,
    "weightedaverageshares": 910723,
    "basicearningslosspersharefromdiscontinuedoperations": -29.13,
    "dilutedearningslosspersharefromdiscontinuedoperations": -2808,
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 3450,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 1172818,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 49050,
    "keymanagementpersonnelcompensationsharebasedpayment": 223286,
    "keymanagementpersonnelcompensation": 1445154,
    "convertibleloans": 4898377,
    "loanswithwarrants": 871420,
    "shortterminvestmentsclassifiedascashequivalents": 100000,
    "loans": 5869797,
    "grossproceedsatdisbursementdate": 5000000,
    "embeddedderivativeseparated": -449898,
    "transactioncostsallocatedtohost": -10236,
    "carryingamountatinitialrecognition": 4539866,
    "interestincomeonimpairedfinancialassetsaccrued": 447945,
    "amortizationtransactioncostsandderivative": 358511,
    "totalconvertibleloans": 5346322,
    "accruedinterests": 447945,
    "balanceatending": 4898377,
    "proportionofownershipinterestinsubsidiary": 1,
    "principalplaceofbusinessofsubsidiary": "Dublin",
    "countryofincorporationorresidenceofsubsidiary": "Ireland",
    "othercashandcashequivalents": 15000,
    "shareissuerelatedcost": 5100000,
    "issueofconvertibleinstruments": 2500000,
    "milestonepayment": 1000000,
    "increasedecreaseinliabilitiesarisingfromfinancingactivities": 9100000,
    "taxterm": 20,
    "currenttaxassets": 41430,
    "numberofoperatingsegment": 1,
    "royaltyterm": 12,
    "aggregateamount": 4375000,
    "leasesamount": 5000,
    "grantedshareoptionpercentage": 0.5,
    "grantedterm": "one year",
    "remaininggrantedpercentage": 0.5,
    "researchanddevelopmentexpenditurespercentage": 0.485,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariablepercent": 0.05,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariableimpactonpretaxearnings": 43977,
    "capitalizedamount": 275281,
    "intangibleassetsacquiredbywayofgovernmentgrant": 1700503,
    "intangibleassetsacquiredbywayofgovernmentgrantatfairvalue": 40653,
    "capitalizednet": 2783431,
    "assetimpairmentcharges": 12397148,
    "offeringprice": 25000000,
    "saleofcommonstockshares": 116843,
    "commonsharesforaggregate": 1505244,
    "proceedsfromissueofordinaryshares": 12100000,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangementshares": 97742,
    "expensefromsharebasedpaymenttransactionswithemployees": 346035,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 346035,
    "exercisepriceofoutstandingsharesoption": 584.66,
    "deferredtaxexpenseincome": 1000000,
    "researchanddevelopmentexpensecapitalization": 1975784,
    "grantcontingentamount": 810252,
    "futuresharegrantcontingent": 360112,
    "employeestockoptions": 342799,
    "actuarialassumptionsminimumretirementsavinginterestrate": 0.01,
    "weightedaveragedurationofdefinedbenefitobligation1": 19.9,
    "gainfromderivativefinancialinstruments": 451131,
    "revaluationgainofderivative": 449898,
    "revaluationofoutstandingwarrants": 1233,
    "financeexpensesincludedinterestpaid": 19503,
    "averageeffectivetaxrate": 0.13699999999999998,
    "deferredtaxassetoperatinglosscarryforwarddescription": "the Group had unrecognized tax loss carryforwards amounting to CHF 103.1 million (2021: CHF 109.9 million), of which CHF 101.4 millionrelated to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.7 million to Altamira TherapeuticsInc. in the United States (2021: CHF 108.6 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.3 millionfor Auris Medical Inc.).",
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 157320,
    "adjustedweightedaverageshares": 910723,
    "warrantstopurchase": 99171,
    "minimumoperatingleasepayments": 6001,
    "auditorsremuneration": 195988,
    "keymanagementpersonnelcompensations": 1038810,
    "expensefromsharebasedpaymenttransactionwithemployees": 183058,
    "adjustmentsforsharebasedpayment": 223286,
    "postemploymentbenefitexpensesdefinedbenefitplans": 49050,
    "relatedpartytransactions": 107110,
    "carryingsamount": 4898377,
    "fairvaluemeasurementamount": 449898,
    "derivativeamount": 310439,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives1": 416003,
    "interestandtransactioncosts": 170893,
    "purchasedshares": 75000,
    "additionalcommonshares": 75000,
    "increasedecreaseinnumberofsharesoutstanding": 397250,
    "exerciseprice": 24,
    "proceedsfromexerciseofwarrants": 1233,
    "entityregistrantname": "Altamira Therapeutics Ltd.",
    "tradingsymbol": "CYTO",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 1180053,
    "amendmentflag": "false",
    "entitycentralindexkey": 1601936,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36582",
    "entityincorporationstatecountrycode": "Bermuda",
    "entityaddressaddressline1": "Clarendon House",
    "entityaddressaddressline2": "2 Church Street",
    "entityaddresscityortown": "Hamilton HM11",
    "entityaddresspostalzipcode": "HM11",
    "entityaddresscountry": "Bermuda",
    "contactpersonnelname": "Thomas Meyer",
    "cityareacode": "+1 (441)",
    "localphonenumber": "295 5950",
    "security12btitle": "Common Shares, par value CHF 0.20 per share",
    "securityexchangename": "The Nasdaq Stock Market LLC",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1235,
    "auditorname": "Roland Mueller",
    "auditorlocation": "Zurich, Switzerland"
  },
  {
    "date": "2021-12-31",
    "symbol": "CYTO",
    "period": "FY",
    "revenue": 63882,
    "costofsales": 2240554,
    "grossprofit": -2176672,
    "otheroperatingincomeexpense": 460710,
    "researchanddevelopmentexpense": 8939037,
    "salesandmarketingexpense": 161167,
    "generalandadministrativeexpense": 4946576,
    "profitlossfromoperatingactivities": -17099793,
    "investmentincome": 3219,
    "interestexpense": 189695,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 328641,
    "gainslossesonchangeinfairvalueofderivatives": -410918,
    "profitlossbeforetax": -17368546,
    "incometaxexpensecontinuingoperations": 21620,
    "profitlossattributabletoownersofparent": -17390166,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": 264984,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 772,
    "othercomprehensiveincome": 264984,
    "totalcomprehensivelossesattributabletoownersofthecompany": -17124410,
    "basicanddilutedlosspershareinfrancspershare": -1.31,
    "propertyplantandequipment": 1,
    "rightofuseassets": 564714,
    "intangibleassetsotherthangoodwill": 14314877,
    "othernoncurrentreceivables": 199105,
    "noncurrentassets": 15078697,
    "inventories": 839221,
    "tradeandothercurrentreceivables": 21746,
    "othercurrentreceivables": 917833,
    "currentprepayments": 996910,
    "cashandcashequivalents": 984191,
    "currentassets": 3759901,
    "assets": 18838598,
    "issuedcapital": 149643,
    "sharepremium": 188511476,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": 62069,
    "retainedearnings": -176018660,
    "equityattributabletoownersofparent": 12704528,
    "noncurrentderivativefinancialliabilities": 1233,
    "noncurrentleaseliabilities": 343629,
    "noncurrentprovisionsforemployeebenefits": 668319,
    "deferredtaxliabilityasset": 142484,
    "noncurrentliabilities": 1273521,
    "othercurrentfinancialliabilities": 114251,
    "tradeandothercurrentpayables": 3697723,
    "accrualsclassifiedascurrent": 1048575,
    "currentliabilities": 4860549,
    "liabilities": 6134070,
    "equityandliabilities": 18838598,
    "equity": 12704528,
    "othercomprehensiveincomebeforetax": -17124410,
    "capitalincreaseexerciseofwarrants": 7104691,
    "transactioncost": -156817,
    "conversionofloanin": 1371255,
    "issueofequity": 3533616,
    "increasedecreasethroughsharebasedpaymenttransactions": 1206303,
    "profitloss": 17390166,
    "adjustmentsfordepreciationexpense": 76357,
    "adjustmentsforimpairmentlossreversalofimpairmentlossrecognisedinprofitorloss": 1529929,
    "adjustmentsforunrealisedforeignexchangelossesgains": -279329,
    "adjustmentsforinterestexpense": 174593,
    "adjustmentsforsharebasedpayments": 1206303,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 65927,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -410918,
    "adjustmentsforincometaxexpense": 21620,
    "adjustmentsforreconcileprofitloss": -14183848,
    "adjustmentsfordecreaseincreaseininventories": -839221,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -586612,
    "adjustmentsforincreasedecreaseinprepayments": -719321,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 2937019,
    "adjustmentsforincreasedecreaseinaccruedexpenses": -280755,
    "cashflowsfromusedinoperations": -13672738,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 3325952,
    "investmentinothernoncurrentreceivables": 179104,
    "cashflowsfromusedininvestingactivities": -3505056,
    "proceedsfromissuingsharesfollowonoffering": 6842940,
    "transactionscost": -156817,
    "repaymentofloan": 50000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 18700,
    "interestpaidclassifiedasfinancingactivities": 3699,
    "cashflowsfromusedinfinancingactivities": 6613724,
    "increasedecreaseincashandcashequivalents": -10564070,
    "effectofexchangeratechangesoncashandcashequivalents": 289391,
    "disclosureofreportingentityexplanatorytextblock": "1.Reporting entity ",
    "rightofuseassetsandleaseliabilitiestextblock": "8. Right-of-useassets and lease liabilities ",
    "disclosureofsalesandmarketingexpensetextblock": "21.Sales and marketing expense ",
    "disclosureofloanstextblock": "29.Loan ",
    "disclosureofwarrantstextblock": "30.Warrants from Public Offering ",
    "consolidationpolicy1policytextblock": "Basisof consolidation ",
    "assetpurchasepolicytextblock": "Assetpurchase ",
    "leasespolicytextblock": "Leases ",
    "inventoriespolicytextblock": "Inventories ",
    "disclosureofdetailedinformationaboutforeigncurrencyratesexplanatorytabletextblock": "      Currency           Geographical    area     Reporting    entities      December 31,    2021      December 31,    2020      December 31,    2019       CHF     Swiss Franc     Switzerland      5       1.0000       1.0000       1.0000       USD     Dollar     United States      1       0.9110       0.8840       0.9674       EUR     Euro     Europe      1       1.0361       1.0817       1.0855       AUD     Dollar     Australia      1       0.6620       0.6822       —    ",
    "estimatedusefullivestabletextblock": "      Production    equipment     5 years      Office    furniture and electronic data processing equipment (“EDP”)     3 years   ",
    "scheduleofresonablyalternativeassumptionsforthevaluationoftheoptioncomponentoftheconvertibleloantabletextblock": "            Dec    31, 2021      Dec    31, 2020             Increase/Decrease     in volatility  assumption      Effect    on result  before taxes on  CHF          Increase/Decrease    in volatility  assumption      Effect    on result  before taxes on  CHF         Change in volatility      —       —       +5%      2,770              —       —       -5%      -5,475    ",
    "scheduleoflowvalueandshorttermleaseexpensestabletextblock": "      Low    value and short-term lease expenses     December 31,    2021      December 31,     2020                            Expense    related to short-term leases      52,280       61,509       Expense    related to leases of low value assets      —       —       Total      52,280       61,509    ",
    "scheduleofleaseliabilitiestabletextblock": "      Lease    liabilities     December 31,    2021          December 31,     2020       As of    January 1      —       —       Additions      594,436       —       Interest    expenses      3,000       —       Repayment    of lease liability      (21,700)      —       As of December 31      575,736       —                              thereof    non-current      461,485       —       thereof current      114,251            ",
    "scheduleofmaturitiesofleaseliabilitiestabletextblock": "      Maturities    of lease liabilities     December 31,    2021      December 31,     2020                            Year 1      130,200       —       Year 2      130,200       —       Year 3      130,200       —       Year 4      130,200       —       Year 5      97,650       —       Undiscounted lease payments      618,450       —       Less:    unearned interest      (42,714)      —       Total      575,736       —   ",
    "disclosureofdetailedinformationforcashandcashequivalentstabletextblock": "            December 31,    2021      December 31,    2020       Cash    in bank accounts      984,191       11,258,870       Cash    on hand      —       —       Total    cash and cash equivalents      984,191       11,258,870   ",
    "componentsofaccruedexpensesandotherliabilitiestabletextblock": "            December 31,    2021      December 31,     2020       Trade    accounts payable - third parties      3,544,384       722,272       Other      153,339       40,181       Total    trade and other payables      3,697,723       762,453   ",
    "disclosureofcomponentsofaccruedexpenses": "            December 31,    2021      December 31,     2020       Accrued    research and development costs including milestone payments      557,391       1,105,089       Professional    fees      179,461       172,273       Accrued    vacation & overtime      51,218       44,466       Employee    benefits incl. share based payments      196,917       101,821       Other      63,588       9,457       Total    accrued expenses      1,048,575       1,433,106   ",
    "scheduleofotheroperatingincometabletextblock": "            December 31,    2021      December 31,    2020      December 31,    2019       Income    from R&D tax incentive (Government grants)      458,157       —       —       Refund    of share issuance stamp duty      —       100,002       —       Other    income      2,553       74,473       —       Total    other operating income      460,710       174,475       —   ",
    "scheduleofcostofsalestabletextblock": "            December 31,    2021      December 31,    2020      December 31,    2019       Product    purchases, packaging and logistics      173,758       —       —       Employee    benefit and expenses      89,238       —       —       Inventory    write-down      1,977,558       —       —       Total    cost of sales      2,240,554       —       —   ",
    "disclosureofsalesandmarketingexpensetabletextblock": "            December 31,    2021      December 31,    2020      December 31,    2019       Marketing    and sales expenses      1,132,864       —       —       Employee    benefits and expenses      204,157       —       —       Product    samples      161,167       —       —       Total    sales and marketing      1,498,218       —       —   ",
    "disclosureofincometaxexpensetabletextblock": "            2021      2020      2019       Deferred    income tax expense      (570,730)      (389,384)      (213,355)      Deferred    income tax gain      549,110       410,668       407,192              (21,620)      21,284       193,837    ",
    "discloureofdeferredtaxesassetsandliabilitiestabletextblock": "      Deferred    Tax Liabilities     December 31,     2021      December 31,    2020       Intangible    assets      (51,914)      (252,174)      Deferred    unrealized foreign exchange gains      —       (350,054)      Other    receivables      (122,449)      —       Total      (174,363)      (602,228)   ",
    "disclosureofdetailedinformationabouttaxlosscarryforwards": "            December 31,    2021      December 31,    2020       Within    1 year      28,909,896       19,575,171       Between    1 and 3 years      50,673,943       56,866,795       Between    3 and 7 years      29,007,049       36,701,692       More    than 7 years      1,264,262       870,200       Total      109,855,150       114,013,858    ",
    "disclosureofdetailedinformationaboutearningspershareexplanatory": "            December 31,    2021      December 31,    2020      December 31,    2019       Loss    attributable to owners of the Company      (17,390,166)      (8,200,165)      (6,631,901)      Weighted    average number of shares outstanding      13,246,281       6,014,146       2,909,056       Basic    and diluted loss per share      (1.31)      (1.36)      (2.28)   ",
    "scheduleofloantextblock": "            December 31,     2021      December 31,     2020       Loan guaranteed by Swiss government    (COVID-19)      —       50,000       Convertible    loan      —       473,920       Total      —       523,920    ",
    "reportingentities": 1,
    "closingforeignexchangerate": 0.662,
    "averageforeignexchangerate": 0.6866,
    "usefullivesordepreciationratespropertyplantandequipmentperiod": 3,
    "financialassets": 1438483,
    "financialliabilities": 5323267,
    "tradeandotherpayables": 3697723,
    "currentaccruedexpensesandothercurrentliabilities": 1048575,
    "currentleaseliabilities": 114251,
    "derivativefinancialinstruments": 576969,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 5323267,
    "financialliabilitieswarrantsfrompublicoffering": "Liability 1,233",
    "issuessettlementsfairvaluemeasurementliabilities": -71700,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": 410918,
    "otherincreasedecreaseinfairvaluemeasurementliabilities": -602926,
    "maximumexposuretocreditrisk": 1261124,
    "riskexposureassociatedwithinstrumentssharingcharacteristic": 1556537,
    "noncurrentasset": 14879592,
    "propertyservicechargeexpense": 29722,
    "cost": 594436,
    "accumulateddepreciation": -29722,
    "netbookvalue1": 564714,
    "additionstorightofuseassets": 594436,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 52280,
    "lowvalueandshorttermleaseexpensestotal": 52280,
    "leaseliabilities": 575736,
    "interestexpenseonleaseliabilities": 3000,
    "repaymentofleaseliability": -21700,
    "thereofnoncurrent": 461485,
    "thereofcurrent": 114251,
    "maturitiesofleaseliabilitiesyear1": 130200,
    "maturitiesofleaseliabilitiesyear2": 130200,
    "maturitiesofleaseliabilitiesyear3": 130200,
    "maturitiesofleaseliabilitiesyear4": 130200,
    "maturitiesofleaseliabilitiesyear5": 97650,
    "undiscountedleasepayments": 618450,
    "lessunearnedinterest": -42714,
    "maturitiesofleaseliabilitiestotal": 575736,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -3654,
    "intangibleassetsotherthangoodwilladditions": 6733050,
    "intangibleassetsotherthangoodwilladditionsnetbookvalue": 15844806,
    "impairmentindollars": -1529929,
    "accumulatedamortizationandimpairmentlosses": -1529929,
    "netbookvalueamount": 14314877,
    "finishedgoods": 839221,
    "inventoriestotal": 839221,
    "valueaddedtaxreceivables": 470958,
    "shareofprofitlossofassociatesandjointventuresaccountedforusingequitymethod": 255187,
    "currentvalueaddedtaxreceivables": 168851,
    "currentreceivablesfromtaxesotherthanincometax": 7336,
    "currentreceivablesfromothersources": 15501,
    "currentprepaymentsandothercurrentassets": 859492,
    "currentprepaidinsurance": 137418,
    "balanceswithbanks": 984191,
    "cash": 984191,
    "numberofsharesissued": 14964261,
    "parvaluepershare": 0.01,
    "numberofsharesoutstanding": 14964261,
    "exerciseofwarrants": 897435,
    "atmprogram": 1184700,
    "sharebasedpaymentsbonus": 174610,
    "conversionconvertibleloan": 516814,
    "sharesissuedfortrasiracquisition": 773543,
    "numberofoutstandingshareoptions": 523881,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "3 years’ service from grant date (50%)",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm2": 8,
    "descriptionofinputsusedinfairvaluemeasuremententitysownequityinstruments": "USD 1.241 (1 year vesting) 2) USD 1.850 (2 year vesting) 2) USD 2.183 (3 year vesting) 2)",
    "sharepriceforfairvaluemeasurementonequity": "USD 3.54",
    "exercisepriceforfairvaluemeasurementonequity": "USD 3.511",
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.013,
    "descriptionofoptionslifeshareoptionsgranted": "1, 2 and 3 years",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0006,
    "numberofoutstandingshareoptionoutstanding": 1329510,
    "weightedaverageexercisepriceoutstanding": 1.65,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions": 7.01,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangements": -51290,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangements": 342263,
    "weightedaverageexercisepricegranted": 2.27,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions1": 6.56,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangements": 288446,
    "tradeandotherpayablestotradesuppliers": 3544384,
    "othercurrentpayables": 153339,
    "currentresearchanddevelopmentprovision": 557391,
    "currentprofessionalfeesaccruals": 179461,
    "currentvacationandovertimeaccruals": 51218,
    "shorttermemployeebenefitsaccruals": 196917,
    "othercurrentliabilities": 63588,
    "accrualclassifiedascurrent": 1048575,
    "incomefromrdtaxincentive": 458157,
    "otherincome": 2553,
    "revenueandoperatingincome": 460710,
    "purchasesofgoodsrelatedpartytransactions": 173758,
    "shorttermemployeebenefitsexpense": 89238,
    "inventorywritedown": 1977558,
    "preclinicalprojects": 587019,
    "clinicalprojects": 2957752,
    "drugmanufacturingandsubstance": 1100453,
    "employeebenefitsresearchanddevelopmentexpense": 1897155,
    "patentsandtrademarks": 465587,
    "regulatoryprojects": 354507,
    "impairmentintangibleassetsindollars": 1529929,
    "depreciationexpenseofresearchanddevelopmenttangibleassets": 46635,
    "generalemployeebenefitsexpense": 1554778,
    "businessdevelopmentexpenses": 967046,
    "travelexpense": 75829,
    "administrativeexpense": 2245862,
    "generalleaseandsubleasepaymentsrecognisedasexpense": 52280,
    "depreciationrightofuseassetsindollars": 29722,
    "capitaltaxexpenses": 21059,
    "wagesandsalaries": 1865633,
    "pensioncosts": 165801,
    "othershorttermemployeebenefits": 275258,
    "expensefromsharebasedpaymentstransactionwithemployees": 1223696,
    "otherpersonnelexpenditures": 214940,
    "employeebenefitsexpense": 3745328,
    "liabilityassetofdefinedbenefitplans": 4677632,
    "pastservicecostnetdefinedbenefitliabilityasset": 162200,
    "currentservicecostnetdefinedbenefitliabilityassetplanparticipantscontribution": 101066,
    "interestcost": 10464,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": 159845,
    "planamendmentsindollars": -3115,
    "paymentsinrespectofsettlementnetdefinedbenefitliabilityasset": -142951,
    "increasedecreasethroughtransfersinofnewemployeesnetdefinedbenefitliabilityasset": 860521,
    "liabilityassetofdefinedbenefitplan": 4009313,
    "adjustmentsforinterestincome": 8586,
    "returnonplanassetsnetdefinedbenefitliabilityasset": 424829,
    "contributionstoplanbyemployernetdefinedbenefitliabilityasset": 101066,
    "contributionstoplanbyplanparticipantsnetdefinedbenefitliabilityasset": 101066,
    "paymentinrespectofsettlementsnetdefinedbenefitliabilityasset": -142951,
    "employeeobligationtobenifittransferinamount": 860521,
    "administrativeexpensesnetdefinedbenefitliabilityasset": -6030,
    "planassetsatfairvalue": 4009313,
    "definedbenefitobligationatpresentvalue": 4677632,
    "currentservicecostnetdefinedbenefitliabilityasset": 159085,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 1878,
    "administrativeexpensenetdefinedbenefitliabilityasset": 6030,
    "postemploymentbenefitexpensedefinedbenefitplans": 166993,
    "actuarialgainslossesarisingfromchangesinfinancialassumptionsnetdefinedbenefitliabilityasset": -74284,
    "actuarialgainslossesarisingfromexperienceadjustmentsnetdefinedbenefitliabilityasset": 463238,
    "actuarialgainslossesarisingfromchangesindemographicassumptionsnetdefinedbenefitliabilityasset": -229109,
    "othercomprehensiveincomebeforetaxgainslossesonremeasurementsofdefinedbenefitplans": -264984,
    "actuarialassumptionofdiscountrates": 0.003,
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.0085,
    "descriptionofassetliabilitymatchingstrategiesusedbyplanorentitytomanagerisk": "BVG2015G",
    "percentageofreasonablypossibleincreaseinactuarialassumptions": "0.25% increase",
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": 98983,
    "lifeexpectancyreasonablypossibleincreaseinactuarialassumption": "+ 1 year",
    "revenuefrominterest": 3219,
    "netforeignexchangegain": 1458429,
    "revaluationgainfromderivativefinancialinstruments": 5085,
    "financeincome": 1466733,
    "interestexpenseincludingbankcharges": 189695,
    "netforeignexchangeloss": 1129788,
    "revaluationlossfromderivativefinancialinstrumentsindollars": -416003,
    "financecosts": 1735486,
    "financeincomecost": -268753,
    "deferredincometaxexpense": -570730,
    "deferredincometaxgain": 549110,
    "incometaxexpensecontinuingoperation": -21620,
    "accountingprofit": -17368546,
    "taxexpenseincomeatapplicabletaxrate": 2348057,
    "incometaxreconciliationunrecognizedtemporarydifferences": -632031,
    "taxeffectoftaxlosses": -1885486,
    "effectofimpairmentofdeferredtaxassets": -75375,
    "incometaxreconciliationdeductionimpactfromapplicationofdifferenttaxrates": 223215,
    "deferredtaxliabilities": 174363,
    "deferredtaxassets": 31879,
    "deferredtaxnet": -142484,
    "deferredtaxliabilitiesasset": -125865,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -21620,
    "exchangedifferences": 5001,
    "deferredtaxliabilitiesassets": -142484,
    "deferredtaxassetoperatinglosscarryforward": 109855150,
    "employeebenefitplan": -87149,
    "otheraccountspayablein": 344822,
    "potentialtaxassets": 431971,
    "netpotentialtaxassetsfromtemporarydifferencesnotrecognized": 431971,
    "potentialtaxassetsfromlosscarryforwardsnotrecognized": 14271306,
    "potentialtaxassetsfromlosscarryforwardsandtemporarydifferencesnotrecognized": 14703277,
    "weightedaverageshares": 13246281,
    "basicanddilutedlosspershare": -1.31,
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 3450,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 946449,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 29467,
    "sharebonuses": 902817,
    "keymanagementpersonnelcompensationsharebasedpayment": 240408,
    "keymanagementpersonnelcompensation": 2119141,
    "balanceatbeginningindollars": 473920,
    "convertedprincipalamount": -644813,
    "interestincomeonimpairedfinancialassetsaccrued": 8348,
    "amortizationtransactioncostsandderivative": 162545,
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofsubsidiary": "●",
    "principalplaceofbusinessofsubsidiary": "Dublin",
    "countryofincorporationorresidenceofsubsidiary": "Ireland",
    "reversestocksplit": "TheCompany effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20.",
    "taxeffectoftaxlosse": 20,
    "currenttaxassets": 31879,
    "assetpurchasedescription": 3,
    "numberofoperatingsegment": 1,
    "usefullivesoramortisationratesintangibleassetsotherthangoodwillperiod": 10,
    "royaltyterm": 12,
    "aggregateamount": 4375000,
    "statementthatlesseeaccountsforshorttermleasesusingrecognitionexemption": "TheGroup applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognitionexemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-valueassets are recognized as expense over the lease term. ",
    "descriptionofequityincentiveplan": "Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”),50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50%vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors grantedfrom 2016 onwards vest after a period of one year after the grant date.",
    "researchanddevelopmentexpenditurespercentage": 0.435,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariablepercent": 0.05,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariableimpactonpretaxearnings": 117247,
    "capitalizeprosecutionregistrationcosts": 55938,
    "capitalizedamount": 2839369,
    "intangibleassetsacquiredbywayofgovernmentgrant": 2783431,
    "intangibleassetsacquiredbywayofgovernmentgrantatfairvalue": 94118,
    "offeringprice": 25000000,
    "saleofcommonstockshares": 1184700,
    "commonsharesforaggregate": 1943318,
    "proceedsfromissueofordinaryshares": 5400000,
    "transactioncosts": 71161,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangementshares": 342263,
    "expensefromsharebasedpaymenttransactionswithemployees": 1206303,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 1223696,
    "exercisepriceofoutstandingsharesoption": 28.79,
    "researchanddevelopmentexpensecapitalization": 2839369,
    "actuarialassumptionsminimumretirementsavinginterestrate": 0.01,
    "weightedaveragedurationofdefinedbenefitobligation1": 19.9,
    "revaluationgainofderivative": 416003,
    "othercomprehensiveincomenetoftaxgainslossesonrevaluation": 5085,
    "netforeigncurrencyexchang": 289961,
    "effectofexchangeratechangesoncashandcashequivalents1": 3700,
    "averageeffectivetaxrate": 0.135,
    "deferredtaxassetoperatinglosscarryforwarddescription": "the Group had unrecognized tax loss carryforwards amounting to CHF 109.9 million (2020: CHF 114.0 million),of which CHF 108.6 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.3 millionto Altamira Therapeutics Inc. in the United States (2020: CHF 113.0 million for Auris Medical AG, Otolanum AG, Zilentin AG and AltamiraMedica AG and CHF 1.0 million for Auris Medical Inc.).",
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 1329510,
    "adjustedweightedaverageshares": 1149761,
    "warrantstopurchase": 246102,
    "minimumoperatingleasepayments": 52280,
    "auditorsremuneration": 14720,
    "feespaymentforotherservices": 161596,
    "keymanagementpersonnelcompensations": 1210472,
    "expensefromsharebasedpaymenttransactionwithemployees": 165245,
    "adjustmentsforsharebasedpayment": 240408,
    "postemploymentbenefitexpensesdefinedbenefitplans": 29467,
    "relatedpartytransactions": 989606,
    "derivativeamount": 310439,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives1": 416003,
    "interestandtransactioncosts": 170893,
    "descriptionoffairvalueofwarrants": "Theunderwriter was granted a 30-day option to purchase up to 1,500,000 (pre-merger) additional common shares and/or 1,500,000 (pre-merger)additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common sharesand/or warrants in the amount of 1,350,000 (pre-merger) warrants. ",
    "increasedecreaseinnumberofsharesoutstanding": 7945000,
    "exerciseprice": 1.2,
    "classofwarrantsorrightsissued": 37501,
    "classofwarrantsorrightsexercisepriceofwarrantsorrights": 100,
    "entityregistrantname": "ALTAMIRATHERAPEUTICS LTD.",
    "tradingsymbol": "CYTO",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 14964261,
    "amendmentflag": "false",
    "entitycentralindexkey": 1601936,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36582",
    "entityincorporationstatecountrycode": "Bermuda",
    "entityaddressaddressline1": "ClarendonHouse",
    "entityaddressaddressline2": "2Church Street",
    "entityaddresscityortown": "HamiltonHM11",
    "entityaddresspostalzipcode": "HM11",
    "entityaddresscountry": "Bermuda",
    "contactpersonnelname": "ThomasMeyer",
    "cityareacode": "+1 (441)",
    "localphonenumber": "295 59 50",
    "security12btitle": "Common Shares, par value CHF 0.01 per share",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorfirmid": 1235,
    "auditorname": "Roland Mueller",
    "auditorlocation": "Zurich,Switzerland"
  },
  {
    "date": "2020-12-31",
    "symbol": "CYTO",
    "period": "FY",
    "otheroperatingincomeexpense": 174475,
    "researchanddevelopmentexpense": 2862979,
    "generalandadministrativeexpense": 2594662,
    "profitlossfromoperatingactivities": -5283166,
    "investmentincome": 258,
    "interestexpense": 135151,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -333553,
    "gainslossesonchangeinfairvalueofderivatives": -2250222,
    "feeandcommissionexpense": 219615,
    "profitlossbeforetax": -8221449,
    "incometaxexpensecontinuingoperations": -21284,
    "netincomeloss": -8200165,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": -26118,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 88862,
    "othercomprehensiveincome": -26118,
    "totalcomprehensivelossesattributabletoownersofthecompany": -8137421,
    "basicanddilutedearningslosspershare": -1.36,
    "propertyplantandequipment": 46636,
    "intangibleassetsotherthangoodwill": 9115410,
    "othernoncurrentreceivables": 20001,
    "noncurrentassets": 151269,
    "othercurrentreceivables": 80861,
    "currentprepayments": 277589,
    "cashandcashequivalents": 11258870,
    "currentassets": 11617320,
    "assets": 20799367,
    "issuedcapital": 114172,
    "sharepremium": 177230300,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": 61297,
    "retainedearnings": -160635879,
    "stockholdersequity": 16769890,
    "noncurrentderivativefinancialliabilities": 6318,
    "noncurrentprovisionsforemployeebenefits": 867376,
    "deferredtaxliabilityasset": 125865,
    "noncurrentliabilities": 999559,
    "currentportionoflongtermborrowings": 523920,
    "currentderivativefinancialliabilities": 310439,
    "tradeandothercurrentpayables": 762453,
    "accrualsclassifiedascurrent": 1433106,
    "currentliabilities": 3029918,
    "liabilities": 840677,
    "equityandliabilities": 20799367,
    "equity": 16769890,
    "profitlossattributabletoownersofparent": -8200165,
    "comprehensiveincomeloss": -8137421,
    "capitalincreaseexerciseofwarrants": 16074996,
    "transactioncost": -636858,
    "increasedecreasethroughsharebasedpaymenttransactions": 368793,
    "reductionparvalue": 1973044,
    "conversionofloanin": 3064247,
    "profitloss": 8200165,
    "adjustmentsfordepreciationexpense": 20036,
    "adjustmentsforunrealisedforeignexchangelossesgains": 10818,
    "adjustmentsforinterestexpense": 127160,
    "adjustmentsforsharebasedpayments": 368793,
    "transactionscosts": -219615,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 80811,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": -2250222,
    "adjustmentsforincometaxexpense": -21284,
    "adjustmentsforreconcileprofitloss": -5143994,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": 254438,
    "adjustmentsforincreasedecreaseinprepayments": 156661,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -175878,
    "adjustmentsforincreasedecreaseinaccruedexpenses": 65303,
    "cashflowsfromusedinoperations": -4843470,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2315232,
    "interestreceivedclassifiedasinvestingactivities": 258,
    "cashflowsfromusedininvestingactivities": -2314974,
    "proceedsfromissuingsharesfollowonoffering": 16074996,
    "transactionscost": -636858,
    "proceedsfromloan": 1522931,
    "cashflowsfromusedinfinancingactivities": 16961069,
    "increasedecreaseincashandcashequivalents": 9802625,
    "effectofexchangeratechangesoncashandcashequivalents": 71525,
    "reportingentities": 1,
    "closingforeignexchangerate": 0.6822,
    "averageforeignexchangerate": 0.6546,
    "usefullivesordepreciationratespropertyplantandequipmentperiod": "P5Y",
    "financialassets": 11268910,
    "financialliabilities": 3036236,
    "tradeandotherpayables": 762453,
    "currentaccruedexpensesandothercurrentliabilities": 1433106,
    "borrowings": 473920,
    "derivativefinancialinstruments": 316757,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 3036236,
    "financialliabilitieswarrantsfrompublicoffering": "Liability 6,318",
    "financialliabilitiesembeddedderivatives": 310439,
    "increasedecreaseinvolatilityassumptionpercentage": -0.05,
    "effectonresultbeforetaxeson": -5475,
    "issuessettlementsfairvaluemeasurementliabilities": 1522931,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": 219315,
    "otherincreasedecreaseinfairvaluemeasurementliabilities": -905922,
    "maximumexposuretocreditrisk": 11268910,
    "riskexposureassociatedwithinstrumentssharingcharacteristic": 9104828,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": -20036,
    "intangibleassetsotherthangoodwilladditionsnetbookvalue": 9115410,
    "intangibleassetsotherthangoodwilladditionsexchangedifferences": 6120,
    "intangibleassetsotherthangoodwilladditions": 2343677,
    "intangibleassetsotherthangoodwilladditionsnetbookvalue1": 9115410,
    "currentadvancestosuppliers": 479,
    "currentvalueaddedtaxreceivables": 38337,
    "currentreceivablesfromtaxesotherthanincometax": 6087,
    "currentreceivablesfromdepositcreditcards": 10040,
    "currentreceivablesfromothersources": 25918,
    "currentprepaymentsandothercurrentassets": 5020,
    "clinicalprojectsandrelatedactivities": 164916,
    "currentprepaidinsurance": 104590,
    "othercurrentprepayments": 3063,
    "balanceswithbanks": 11258870,
    "cash": 11258870,
    "numberofsharesissued": 11417159,
    "parvaluepershare": 0.4,
    "numberofsharesoutstanding": 11417159,
    "exerciseofwarrants": 1263845,
    "lpcequityline": 1610120,
    "atmprogram": 1628827,
    "sharebasedpaymentsbonus": 51418,
    "conversionconvertibleloan": 737000,
    "registereddirectoffering": 2000000,
    "numberofoutstandingshareoptions": 399738,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "3 years' service from grant date (50%)",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm2": "P8Y",
    "descriptionofinputsusedinfairvaluemeasuremententitysownequityinstruments": "USD 0.258 (1 year vesting) 2) USD 0.514 (2 year vesting) 2) USD 0.578 (3 year vesting) 2)",
    "sharepriceforfairvaluemeasurementonequity": "USD 0.92",
    "exercisepriceforfairvaluemeasurementonequity": "USD 0.825",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.909,
    "descriptionofoptionslifeshareoptionsgranted": "1, 2 and 3 years",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0061,
    "numberofoutstandingshareoptionoutstanding": 1038537,
    "weightedaverageexercisepriceoutstanding": 1.58,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions": "P7Y219D",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangements": 714484,
    "weightedaverageexercisepricegranted": 0.87,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangements": 37576,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptionsexercisable": "P7Y3D",
    "tradeandotherpayablestotradesuppliers": 722272,
    "othercurrentpayables": 40181,
    "currentresearchanddevelopmentprovision": 1105089,
    "currentprofessionalfeesaccruals": 172273,
    "currentvacationandovertimeaccruals": 44466,
    "shorttermemployeebenefitsaccruals": 101821,
    "othercurrentliabilities": 9457,
    "accrualclassifiedascurrent": 1433106,
    "preclinicalprojects": 242617,
    "clinicalprojects": 476972,
    "drugmanufacturingandsubstance": 614744,
    "employeebenefitsresearchanddevelopmentexpense": 1120814,
    "leaseandsubleasepaymentsrecognisedasexpense": 34147,
    "patentsandtrademarks": 246592,
    "regulatoryprojects": 110612,
    "depreciationexpenseofresearchanddevelopmenttangibleassets": 16481,
    "generalemployeebenefitsexpense": 811373,
    "businessdevelopmentexpenses": 95663,
    "travelexpense": 28898,
    "administrativeexpense": 1645530,
    "generalleaseandsubleasepaymentsrecognisedasexpense": 13871,
    "depreciationexpense": 3555,
    "capitaltaxexpenses": -4228,
    "wagesandsalaries": 1260359,
    "pensioncosts": 156843,
    "othershorttermemployeebenefits": 116290,
    "expensefromsharebasedpaymentstransactionwithemployees": 351401,
    "otherpersonnelexpenditures": 47295,
    "employeebenefitsexpense": 1932188,
    "liabilityassetofdefinedbenefitplans": 3529602,
    "liabilityassetofdefinedbenefitplan": 2662226,
    "definedbenefitobligationatpresentvalue": 3529602,
    "planassetsatfairvalue": -2662226,
    "pastservicecostnetdefinedbenefitliabilityasset": 151624,
    "currentservicecostnetdefinedbenefitliabilityassetplanparticipantscontribution": 76032,
    "interestcost": 9482,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": 58912,
    "paymentsinrespectofsettlementnetdefinedbenefitliabilityasset": -201310,
    "increasedecreasethroughtransfersinofnewemployeesnetdefinedbenefitliabilityasset": 346915,
    "adjustmentsforinterestincome": 7429,
    "returnonplanassetsnetdefinedbenefitliabilityasset": 32794,
    "contributionstoplanbyemployernetdefinedbenefitliabilityasset": 76032,
    "contributionstoplanbyplanparticipantsnetdefinedbenefitliabilityasset": 76032,
    "paymentinrespectofsettlementsnetdefinedbenefitliabilityasset": -201310,
    "employeeobligationtobenifittransferinamount": 346915,
    "administrativeexpensesnetdefinedbenefitliabilityasset": -3166,
    "currentservicecostnetdefinedbenefitliabilityasset": 151624,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 2053,
    "administrativeexpensenetdefinedbenefitliabilityasset": 3166,
    "postemploymentbenefitexpensedefinedbenefitplans": 156843,
    "actuarialgainslossesarisingfromchangesinfinancialassumptionsnetdefinedbenefitliabilityasset": 13031,
    "actuarialgainslossesarisingfromexperienceadjustmentsnetdefinedbenefitliabilityasset": 45881,
    "othercomprehensiveincomebeforetaxgainslossesonremeasurementsofdefinedbenefitplans": 26118,
    "actuarialassumptionofdiscountrates": 0.002,
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.006,
    "descriptionofassetliabilitymatchingstrategiesusedbyplanorentitytomanagerisk": "BVG2015G",
    "percentageofreasonablypossibleincreaseinactuarialassumptions": "0.25% increase",
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": 88215,
    "lifeexpectancyreasonablypossibleincreaseinactuarialassumption": "+ 1 year",
    "revenuefrominterest": 258,
    "netforeignexchangegain": 3207649,
    "financeincome": 3207907,
    "interestexpenseincludingbankcharges": 135151,
    "netforeignexchangeloss": 3541202,
    "revaluationlossfromderivativefinancialinstrumentsindollars": -2250222,
    "otherfinancecost": 219615,
    "financecosts": 6146190,
    "financeincomecost": -2938283,
    "deferredincometaxexpense": -389384,
    "deferredincometaxgain": 410668,
    "incometaxexpensecontinuingoperation": 21284,
    "accountingprofit": -8221449,
    "taxexpenseincomeatapplicabletaxrate": 991120,
    "incometaxreconciliationunrecognizedtemporarydifferences": -302557,
    "taxeffectoftaxlosses": -184881,
    "incometaxreconciliationpreviouslyunrecogniseddeferredtaxasset": 97458,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 47894,
    "incometaxreconciliationdeductionimpactfromapplicationofdifferenttaxrates": -531962,
    "deferredtaxliabilities": 602228,
    "deferredtaxassets": 476363,
    "deferredtaxliabilityassets": -125865,
    "deferredtaxliabilitiesasset": -125865,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 21284,
    "deferredtaxassetoperatinglosscarryforward": 114013858,
    "employeebenefitplan": -113106,
    "derivativefinancialinstrumentsin": 36973,
    "otheraccountspayablein": 258303,
    "potentialtaxassets": 408382,
    "propertyandequipmentunrecognizedtemporarydifferences": 19359,
    "unrecognizedpotentialtaxliabilities": 19359,
    "offsettingpotentialtaxliabilities": -19359,
    "netpotentialtaxassetsfromtemporarydifferencesnotrecognized": 389023,
    "potentialtaxassetsfromlosscarryforwardsnotrecognized": 14896367,
    "potentialtaxassetsfromlosscarryforwardsandtemporarydifferencesnotrecognized": 15285390,
    "weightedaverageshares": 6014146,
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 25580,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 570623,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 26870,
    "keymanagementpersonnelcompensationsharebasedpayment": 261988,
    "keymanagementpersonnelcompensation": 859481,
    "grossproceedsatdisbursementdate": 1500000,
    "embeddedderivativeseparated": -230974,
    "transactioncostsallocatedtohost": -22495,
    "carryingamountatinitialrecognition": 1246531,
    "convertedprincipalamount": -895455,
    "interestincomeonimpairedfinancialassetsaccrued": 31920,
    "amortizationtransactioncostsandderivative": 90923,
    "totalconvertibleloanagreement": 473920,
    "nameofsubsidiary": "Auris Medical Pty Ltd",
    "principalplaceofbusinessofsubsidiary": "Collingwood",
    "countryofincorporationorresidenceofsubsidiary": "Australia",
    "proportionofownershipinterestinsubsidiary": 1,
    "reversestocksplit": "The Company effected the 2019 Reverse Share Split of its common shares at a ratio of 1-for-20.",
    "taxeffectoftaxlosse": "P20Y",
    "currenttaxassets": 476363,
    "numberofoperatingsegments": 1,
    "usefullivesoramortisationratesintangibleassetsotherthangoodwillperiod": "P10Y",
    "descriptionofequityincentiveplan": "Under the Auris Medical Holding Ltd. Long Term Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d; or &#x201c;EIP&#x201d;), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.",
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariablepercent": 0.05,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariableimpactonpretaxearnings": 13648,
    "capitalizeprosecutionregistrationcosts": 177623,
    "capitalizedamount": 2343677,
    "offeringprice": 25000000,
    "saleofcommonstockshares": 1628827,
    "commonsharesforaggregate": 1758618,
    "proceedsfromissueofordinaryshares": 3200000,
    "saleofstock": 98954,
    "aggregateofferingprice": 978415000000,
    "transactioncosts": 71161,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangementshares": 726637,
    "expensefromsharebasedpaymenttransactionswithemployees": 368793,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 351401,
    "exercisepriceofoutstandingsharesoption": 27.93,
    "researchanddevelopmentexpensecapitalization": 2343677,
    "actuarialassumptionsminimumretirementsavinginterestrate": 0.01,
    "weightedaveragedurationofdefinedbenefitobligation1": "P21Y328D",
    "revaluationgainofderivative": 2248257,
    "othercomprehensiveincomenetoftaxgainslossesonrevaluation": 1965,
    "effectofexchangeratechangesoncashandcashequivalents1": 71525,
    "averageeffectivetaxrate": 0.121,
    "deferredtaxassetoperatinglosscarryforwarddescription": "the Group had unrecognized tax loss carryforwards amounting to CHF 114.0 million (2019: CHF 151.5 million), of which CHF 113.0 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.0 million to Auris Medical Inc. in the United States and CHF 0.0 million to Auris Medical PTY in Australia (2019: CHF 150.4 million for Auris Medical AG, Auris Medical Holding Ltd. and Otolanum AG and CHF 1.1 million for Auris Medical Inc.).",
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 1038537,
    "adjustedweightedaverageshares": 633314,
    "warranttopurchaseofcommonstock": 1143537,
    "minimumoperatingleasepayments": 50260,
    "auditorsremuneration": 173030,
    "feespaymentforotherservices": 3025,
    "keymanagementpersonnelcompensations": 522237,
    "expensefromsharebasedpaymenttransactionwithemployees": 163476,
    "adjustmentsforsharebasedpayment": 261988,
    "postemploymentbenefitexpensesdefinedbenefitplans": 26870,
    "relatedpartytransactions": 769101,
    "classofwarrantsorrightsexercisepriceofwarrantsorrights": 100,
    "unconvertedoutstandingloanamounted": 473920,
    "outstandingloanunitsamount": 310439,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives1": 2248257,
    "interestandtransactioncosts": 127418,
    "classofwarrantsorrightsissued": 37501,
    "fairvalueofwarrants": 6318,
    "derivativerevaluationdescription": "no Series B warrants were outstanding and subject to revaluation on December 31, 2020. As of December 31, 2019, the number of Series B warrants outstanding subject to revaluation were 34,535 and the fair value amounted to CHF 0.00. Accordingly, there was no revaluation gain or loss on these warrants for the year ended December 31, 2020 (2019: revaluation gain of CHF 215,572).",
    "entityregistrantname": "Auris Medical Holding Ltd.",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 12869587,
    "amendmentflag": "false",
    "entitycentralindexkey": 1601936,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentannualreport": "true",
    "documentshellcompanyreport": "false",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-36582",
    "entityincorporationstatecountrycode": "D0",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-12-31",
    "symbol": "CYTO",
    "period": "FY",
    "entityregistrantname": "Auris Medical Holding Ltd.",
    "entitycentralindexkey": 1601936,
    "documenttype": "20-F",
    "documentperiodenddate": "2019-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 4125949,
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entityinteractivedatacurrent": "No",
    "entityincorporationstatecountrycode": "D0",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36582",
    "researchanddevelopmentexpense": 3325281,
    "generalandadministrativeexpense": 3933863,
    "profitlossfromoperatingactivities": -7259144,
    "investmentincome": 17882,
    "interestexpense": 28628,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -219573,
    "gainsonchangeinfairvalueofderivatives": 663725,
    "profitlossbeforetax": -6825738,
    "incometaxexpensecontinuingoperations": -193837,
    "profitloss": -6631901,
    "othercomprehensiveincomenetoftaxgainslossesonremeasurementsofdefinedbenefitplans": -72010,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 16446,
    "othercomprehensiveincome": -72010,
    "comprehensiveincome": -6703911,
    "basicanddilutedearningslosspershare": -2.28,
    "propertyplantandequipment": 66672,
    "intangibleassetsotherthangoodwill": 4849511,
    "othernoncurrentreceivables": 20001,
    "noncurrentassets": 6852286,
    "othercurrentreceivables": 335299,
    "currentprepayments": 434231,
    "derivativefinancialassets": 219615,
    "cashandcashequivalents": 1384720,
    "currentassets": 2373865,
    "assets": 9226151,
    "issuedcapital": 1650380,
    "sharepremium": 157191707,
    "reserveofchangeinvalueofforeigncurrencybasisspreads": -27565,
    "retainedearnings": -152778389,
    "equity": -152778389,
    "noncurrentderivativefinancialliabilities": 4353,
    "noncurrentprovisionsforemployeebenefits": 760447,
    "deferredtaxliabilityasset": 147149,
    "noncurrentliabilities": 911949,
    "tradeandothercurrentpayables": 938247,
    "accrualsclassifiedascurrent": 1339822,
    "currentliabilities": 2278069,
    "liabilities": 4353,
    "equityandliabilities": 9226151,
    "profitlossattributabletoownersofparent": -6631901,
    "capitalincreaseexerciseofwarrants": 8853599,
    "transactioncost": -948615,
    "increasedecreasethroughsharebasedpaymenttransactions": 228920,
    "adjustmentsfordepreciationexpense": 30823,
    "adjustmentsforunrealisedforeignexchangelossesgains": 21290,
    "adjustmentsforinterestexpense": 1205,
    "adjustmentsforsharebasedpayments": 226601,
    "adjustmentsforincreasedecreaseinemployeebenefitliabilities": 40150,
    "adjustmentsforgainslossesonchangeinfairvalueofderivatives": 663725,
    "adjustmentsforincometaxexpense": -193837,
    "adjustmentsforreconcileprofitloss": -7169394,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -18925,
    "adjustmentsforincreasedecreaseinprepayments": -82948,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -898088,
    "adjustmentsforincreasedecreaseinaccruedexpenses": -224077,
    "cashflowsfromusedinoperations": -8393432,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 63600,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 2955036,
    "interestreceivedclassifiedasinvestingactivities": 17882,
    "cashflowsfromusedininvestingactivities": -3000754,
    "proceedsfromissuingsharesfollowonoffering": 9793643,
    "transactionscosts": 948615,
    "repaymentofloan": 1463328,
    "interestpaidclassifiedasfinancingactivities": 3745,
    "cashflowsfromusedinfinancingactivities": 7377955,
    "increasedecreaseincashandcashequivalents": -4016231,
    "effectofexchangeratechangesoncashandcashequivalents": 7744,
    "nameofsubsidiary": "Auris Medical Ltd.",
    "principalplaceofbusinessofsubsidiary": "Dublin",
    "countryofincorporationorresidenceofsubsidiary": "Ireland",
    "proportionofownershipinterestinsubsidiary": 1,
    "numberofsharesoutstanding": 4125949,
    "parvaluepershare": 0.4,
    "deferredtaxasset": 91851,
    "reversestocksplitratio": "10-for-1",
    "reportingentities": 1,
    "closingforeignexchangerate": 1,
    "averageforeignexchangerate": 1.1128,
    "usefullivesordepreciationratespropertyplantandequipmentperiod": "P5Y",
    "usefullivesoramortisationratesintangibleassetsotherthangoodwillperiod": "P10Y",
    "numberofoperatingsegment": 1,
    "financialassets": 219615,
    "financialliabilities": 4353,
    "tradeandotherpayables": 938247,
    "currentaccruedexpensesandothercurrentliabilities": 1339822,
    "derivativefinancialinstruments": 4353,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 2282422,
    "issuessettlementsfairvaluemeasurementliabilities": -1463328,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": -663725,
    "otherincreasedecreaseinfairvaluemeasurementliabilities": 20678,
    "maximumexposuretocreditrisk": 80040,
    "riskexposureassociatedwithinstrumentssharingcharacteristic": -750949,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariablepercent": 0.05,
    "sensitivityanalysisfortypesofmarketriskreasonablypossiblechangeinriskvariableimpactonpretaxearnings": 28841,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": -30823,
    "disposalspropertyplantandequipment": 236462,
    "intangibleassetsotherthangoodwilladditions": 239593,
    "capitalizedamount": 3230373,
    "prosecutionandregistrationcosts": 239593,
    "currentvalueaddedtaxreceivables": 26438,
    "currentreceivablesfromtaxesotherthanincometax": 24113,
    "currentreceivablesfromdepositcreditcards": 80040,
    "currentreceivablesfromothersources": 204708,
    "currentadvancestosuppliers": 40461,
    "clinicalprojectsandrelatedactivities": 265842,
    "currentprepaidinsurance": 114016,
    "othercurrentprepayments": 13912,
    "balanceswithbanks": 1383182,
    "cashonhand": 1538,
    "numberofsharesissued": 4125949,
    "increasedecreaseinnumberofsharesoutstanding": 7945000,
    "shareissuerelatedcost": 1650379.6,
    "numberofsharessold": 98954,
    "proceedsfromissueofordinaryshares": 978415,
    "adjustmentsoftransactioncosts": 71161,
    "numberofoutstandingshareoptions": 122782,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "3 years' service from grant date (50%)",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm2": "P8Y",
    "descriptionofinputsusedinfairvaluemeasuremententitysownequityinstruments": "USD 1.390 (3 year vesting)",
    "sharepriceforfairvaluemeasurementonequity": 5.75,
    "exercisepriceforfairvaluemeasurementonequity": 5.98,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.9338,
    "descriptionofoptionslifeshareoptionsgranted": "1,2 and 3 years",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0292,
    "numberofoutstandingshareoptionoutstanding": 324053,
    "numberofshareoptionsreplacementofhistoricalgrants": -992777,
    "numberofshareoptionsnewgrantwithnewexerciseprice": 39191,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangements": -66567,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangements": 351429,
    "numberofoutstandingshareoption": 3.01,
    "numberofshareoptiongrantedinsharebasedpaymentarrangement": 3.3,
    "weightedaverageremainingcontractuallifesofoutstandingshareoptions": "P7Y5M12D",
    "weightedaverageremainingcontractuallifesofgrantshareoptions": "P0Y",
    "weightedaverageremainingcontractuallifesofoutstandingshareoptionsexercisable": "P0Y",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangementshares": 390620,
    "expensefromsharebasedpaymenttransactionswithemployees": 2318,
    "exercisepriceofoutstandingsharesoption": 5.56,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 228920,
    "payablesforpurchaseofnoncurrentassets": 2319,
    "tradeandotherpayablestotradesuppliers": 906501,
    "othercurrentpayables": 31746,
    "currentresearchanddevelopmentprovision": 1019563,
    "currentprofessionalfeesaccruals": 108519,
    "currentvacationandovertimeaccruals": 23377,
    "shorttermemployeebenefitsaccruals": 47916,
    "othercurrentliabilities": 140447,
    "accrualclassifiedascurrent": 1339822,
    "preclinicalprojects": 182346,
    "clinicalprojects": 993085,
    "drugmanufacturingandsubstance": 481453,
    "employeebenefitsresearchanddevelopmentexpense": 1373543,
    "leaseandsubleasepaymentsrecognisedasexpense": 26057,
    "patentsandtrademarks": 168367,
    "regulatoryprojects": 80347,
    "depreciationexpenseofresearchanddevelopmenttangibleassets": 20083,
    "researchanddevelopmentexpensecapitalization": 3230373,
    "generalemployeebenefitsexpense": 1010708,
    "businessdevelopmentexpenses": 113959,
    "travelexpense": 102679,
    "administrativeexpense": 2653914,
    "generalleaseandsubleasepaymentsrecognisedasexpense": 27362,
    "depreciationexpense": 10740,
    "capitaltaxexpenses": 14501,
    "wagesandsalaries": 1832382,
    "pensioncosts": 130792,
    "othershorttermemployeebenefits": 217448,
    "expensefromsharebasedpaymentstransactionwithemployees": 226601,
    "otheremployeeexpense": 22973,
    "employeebenefitsexpense": 2384250,
    "liabilityassetofdefinedbenefitplans": 3087947,
    "pastservicecostnetdefinedbenefitliabilityasset": 138580,
    "currentservicecostnetdefinedbenefitliabilityassetplanparticipantscontribution": 107618,
    "interestcost": 27335,
    "gainlossonremeasurementofnetdefinedbenefitliabilityasset": -145385,
    "paymentsinrespectofsettlementnetdefinedbenefitliabilityasset": -445457,
    "increasedecreasethroughtransfersinofnewemployeesnetdefinedbenefitliabilityasset": 28861,
    "liabilityassetofdefinedbenefitplan": 2327500,
    "adjustmentsforinterestincome": 22198,
    "returnonplanassetsnetdefinedbenefitliabilityasset": -73375,
    "contributionstoplanbyemployernetdefinedbenefitliabilityasset": 107618,
    "contributionstoplanbyplanparticipantsnetdefinedbenefitliabilityasset": 107618,
    "paymentinrespectofsettlementsnetdefinedbenefitliabilityasset": -445457,
    "employeeobligationtobenifittransferinamount": 28861,
    "administrativeexpensesnetdefinedbenefitliabilityasset": -4051,
    "definedbenefitobligationatpresentvalue": 3087947,
    "planassetsatfairvalue": 2327500,
    "currentservicecostnetdefinedbenefitliabilityasset": 138580,
    "interestexpenseincomenetdefinedbenefitliabilityasset": 5137,
    "administrativeexpensenetdefinedbenefitliabilityasset": 4051,
    "postemploymentbenefitexpensedefinedbenefitplans": 147768,
    "actuarialgainslossesarisingfromchangesinfinancialassumptionsnetdefinedbenefitliabilityasset": 360541,
    "actuarialgainslossesarisingfromexperienceadjustmentsnetdefinedbenefitliabilityasset": -215156,
    "othercomprehensiveincomebeforetaxgainslossesonremeasurementsofdefinedbenefitplans": 72010,
    "actuarialassumptionofdiscountrates": 0.003,
    "actuarialassumptionofexpectedratesofsalaryincreases": 0.011,
    "descriptionofassetliabilitymatchingstrategiesusedbyplanorentitytomanagerisk": "BVG2015G",
    "percentageofreasonablypossibleincreaseinactuarialassumption": 0.25,
    "increasedecreaseindefinedbenefitobligationduetoreasonablypossibleincreaseinactuarialassumption": 73484,
    "lifeexpectancyreasonablypossibleincreaseinactuarialassumption": "P1Y",
    "weightedaveragedurationofdefinedbenefitobligation1": "P22Y7M6D",
    "actuarialassumptionsminimumretirementsavinginterestrate": 0.01,
    "revenuefrominterest": 17882,
    "netforeignexchangegain": 1343153,
    "gainslossesonchangeinfairvalueofderivatives": 663725,
    "financeincome": 2024760,
    "interestexpenseincludingbankcharges": 28628,
    "netforeignexchangeloss": 1562725,
    "financecosts": 1591353,
    "financeincomecost": 433407,
    "effectofexchangeratechangesoncashandcashequivalent": 7744,
    "deferredincometaxexpense": -213355,
    "deferredincometaxgain": 407192,
    "incometaxexpensecontinuingoperation": 193837,
    "accountingprofit": -6825738,
    "taxexpenseincomeatapplicabletaxrate": 854636,
    "incometaxreconciliationunrecognizedtemporarydifferences": 89974,
    "taxeffectoftaxlosses": -913309,
    "effectofutilizationofpreviouslyunrecognizedtaxablelosses": 193155,
    "effectofimpairmentofdeferredtaxassets": -131055,
    "incometaxreconciliationpreviouslyunrecogniseddeferredtaxasset": 20977,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": -29549,
    "effectofchangesinlocaltaxlegislationandorlocaltaxrates": 110758,
    "incometaxreconciliationdeductionimpactfromapplicationofdifferenttaxrates": -1750,
    "deferredtaxliabilities": 26156,
    "deferredtaxassets": 91851,
    "deferredtaxliabilityassets": -147149,
    "deferredtaxliabilitiesasset": -26156,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 213355,
    "deferredtaxassetoperatinglosscarryforward": 1054465,
    "assetsliabilitiesofbenefitplan": -99162,
    "stockoptionplan": -568,
    "potentialtaxassets": 99730,
    "potentialtaxassetsfromlosscarryforwardsnotrecognized": 19611272,
    "potentialtaxassetsfromlosscarryforwardsandtemporarydifferencesnotrecognized": 19711002,
    "averageeffectivetaxrate": 0.125,
    "deferredtaxassetoperatinglosscarryforwarddescription": "Amounting to CHF 151.5 million (2018: CHF 151.4 million), of which CHF 150.4 million related to Auris Medical AG, Auris Medical Holding Ltd. and Otolanum AG in Switzerland and CHF 1,1 million to Auris Medical Inc. in the United States (2018: CHF 150.3 million for Auris Medical AG and Otolanum AG and CHF 1.1 million for Auris Medical Inc.).",
    "weightedaverageshares": 2909056,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 324053,
    "adjustedweightedaverageshares": 812167,
    "warranttopurchaseofcommonstock": 2488520,
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 24980,
    "minimumoperatingleasepayments": 49314,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 170755,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 42560,
    "keymanagementpersonnelcompensationsharebasedpayment": 49323,
    "keymanagementpersonnelcompensation": 220078,
    "keymanagementpersonnelcompensations": 934179,
    "expensefromsharebasedpaymenttransactionwithemployees": 170755,
    "adjustmentsforsharebasedpayment": 159235,
    "postemploymentbenefitexpensedefinedbenefitplan": 42560,
    "relatedpartytransactions": 271999,
    "feespaymentforotherservices": 28611,
    "auditorsremuneration": 11770,
    "numberofsharesofcommonsharesexercisablebywarrantsoutstanding": 100,
    "classofwarrantsorrightsexercisepriceofwarrantsorrights": 1.2,
    "proceedsfromissuingshares": 1132762,
    "warrantsorrightsoutstanding1": 81138,
    "increasedecreaseinfairvaluemeasurementwarrantsorrights": 2479394,
    "fairvalueofwarrants": 166301,
    "revaluationgainofderivative": 285298,
    "descriptionoffairvalueofwarrants": "The fair value of the warrants amounted to CHF [0]. Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF [0], resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF [0])."
  }
]